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ABBREVIATIONS 
 
 
 
ASCT autologous stem cell transplantation 
ATM ataxia telangiectasia mutated gene 
BCL1 B-cell leukaemia/lymphoma 1 (alias: CCND1, PRAD1) gene 
BCL2 B-cell leukaemia/lymphoma 2 gene 
BCL6 B-cell CLL/lymphoma 6 (alias: LAZ3) gene 
BCNU carmustine 
BEAC carmustine (BCNU), etoposide, cytarabine (araC), cyclophosphamide 
BEAM carmustine (BCNU), etoposide, cytarabine (araC), melphalan 
BMI-1 B-cell-specific Moloney murine leukaemia virus integration site 1 gene 
CCND1 coding for cyclin D1 (alias: BCL1, PRAD1) gene 
CD cluster of differentiation 
CDK cyclin dependent kinase 
CGH comparative genomic hybridisation 
CHOP cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine  
 (Oncovin®), prednisone 
CI confidence interval 
CLL chronic lymphocytic leukaemia 
cM centiMorgan 
CMYC Avian myelocytomatosis viral oncogene 
CNOP cyclophosphamide, mitoxantrone (Novantrone®), vincristine  
 (Oncovin®), prednisone 
CNS central nervous system 
COP cyclophosphamide, vincristine (Oncovin®), prednisone 
CR complete remission 
CRP C-reactive protein 
CVP cyclophosphamide, vincristine, prednisone 
DNA deoxyribonucleic acid 
dUTP deoxyuridine triphosphate 
E2F a transcription factor 
EFS event-free survival 
ESHAP etoposide, methylprednisolone (S-Hydril®), cytarabine (araC), cisplatin  
 (Platinol®) 
FADD Fas-associated via death domain gene 
FISH fluorescence in situ hybridisation 
G-CSF granulocyte colony-stimulating factor 
Hpf high power field 
Hyper-CVAD cyclophosphamide, vincristine, doxorubicin (Adriamycin®), dexamethasone, 
high-dose methotrexate, high-dose cytarabine 
Ig immunoglobulin 
IPI International Prognostic Index 
Kb kilobase 
LAZ3 a zinc finger encoding gene (alias: BCL6) 
LDH lactate dehydrogenase 
LOH loss of heterozygosity 
MALT mucosa-associated lymphoma type 
M-BACOD bleomycin, doxorubicin (Adriamycin®), cyclophosphamide, vincristine  
 (Oncovin®), dexamethasone, high-dose methotrexate 
MCL mantle cell lymphoma 
mRNA messenger ribonucleic acid 
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MTC major translocation cluster 
MZ mantle zone 
ND not definable 
NHL non-Hodgkin’s lymphoma 
NR not reported 
NS not significant 
OS overall survival 
p chromosome short arm 
PBSC peripheral blood stem cell 
PCR polymerase chain reaction 
PDCD1 programmed cell death 1 gene 
PFS progression-free survival 
PPP2R1B gene for the β isoform of the A subunit of the serine/threonine protein   
 phosphatase 2A  
PR partial response 
PRAD1 parathyroid adenomatosis 1 (alias: BCL1, CCND1) gene 
pRb retinoblastoma protein 
PS performance status 
q chromosome long arm 
RAIDD RIPK1 domain containing adapter with death domain gene 
REAL Revised European-American Lymphoma Classification 
RNA ribonucleic acid 
RR relative risk 
s.c. subcutaneously 
SCT stem cell transplantation 
SLL small lymphocytic lymphoma 
t translocation 
T-PLL T-cell prolymphocytic leukaemia 
TBI total body irradiation 
TTF time to treatment failure 
WF Working formulation 
WHO World Health Organization 
YAC yeast artificial chromosome  
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ABSTRACT 
 
 
 
Mantle cell lymphoma (MCL), characterised by the t(11;14)(q13;q32), was established 
as a subtype of non-Hodgkin’s lymphoma in the early 1990’s. There is still much to be 
learned about this novel disease entity, in particular, there is a lack of knowledge about 
the prognostic factors and optimal treatment of MCL. The aim of this thesis was to 
investigate the clinicopathological features, treatment results, and outcome of MCL 
patients, and to examine the relative prognostic value of several clinicopathological 
factors.  
 
This retrospective series consists of 127 consecutive patients diagnosed with MCL in 
the Helsinki University Central Hospital in 1980 - 1999. The median age of the patients 
was 65 years, and 83% presented with advanced disease. Of the actively treated patients 
45% achieved complete remission, but the median duration of remission was only 16 
months. The long-term prognosis was poor with a median survival of 34 months. First-
line treatment with anthracycline-containing therapy showed no clear survival benefit 
over chemotherapy not containing anthracycline. Three histological subtypes of MCL 
were defined and these types were associated with prognostic significance: 1) the 
mantle zone/nodular subtype of the common variant was diagnosed in 19% of the 
patients and the median survival time was 70 months. 2) The diffuse subtype of the 
common variant (64%) was associated with a median survival of 35 months, and 3) the 
blastoid variant (17%) with a median survival of 11 months (p < 0.001). A high cell 
proliferation index was associated with the blastoid variant and poor survival in general. 
A subset of common MCLs had also enhanced proliferation as assessed by a high Ki-67 
expression (≥ 26% of cells, the upper tertile), which predicted short survival (median 20 
vs. 45 months, p < 0.001) in these patients. The results of multivariate analyses 
suggested that the International Prognostic Index may not be an optimal prognostic tool 
for MCL, and that a better prognostic index might be obtained by combining Ki-67, and 
possibly the histological subtype, together with age, stage, and serum LDH (lactate 
dehydrogenase). 
 
Blastoid transformation during the course of the disease occurred in 35% (18/52) of the 
patients. The minimum estimated risk of transformation was 42% at 5 years. An 
elevated serum LDH level, leukocytosis, and a high cell proliferation rate at diagnosis 
were associated with an increased risk of transformation. Importantly, CNS involvement 
was associated with the blastoid morphology in five of the seven patients who 
developed CNS relapse during the follow-up. 
 
DNA copy number changes were studied by comparative genomic hybridisation (n= 34) 
and these changes turned out to be complex but concentrated to highly specific regions. 
A gain in 3q (52%) and a deletion at 11q22 (30%) were the most frequent and important 
Abstract 
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findings. The mean number of changes was higher in the blastoid variant than in the 
common MCL, as well as in samples taken at relapse than in those taken from untreated 
lymphoma of the same patient.  
 
Of the 48 consecutive MCL patients originally scheduled for autologous stem cell 
transplantation (ASCT) in five Finnish transplantation centres in 1995-2000, altogether 
35 patients underwent ASCT. ASCT was an effective treatment: the overall response 
rate was 94%, and the expected 4-year survival 69%. However, there was no plateau in 
the event-free survival curve after ASCT. Patients transplanted after relapse had a 
similar outcome than those transplanted as first- or second-line treatment for lymphoma. 
An elevated serum C-reactive protein level at diagnosis and an age over 60 years at 
transplantation were associated with a poor outcome after ASCT. 
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INTRODUCTION 
 
 
 
Non-Hodgkin’s lymphomas (NHLs) are a heterogeneous group of lymphoid malignancies 
with large variation in course of the disease and prognosis [1]. During past decade 
increasing knowledge of the biology of the immune system and molecular genetics related 
to NHLs have led to the recognition of a number of new clinicopathological entities [2, 3]. 
One of these is the mantle cell lymphoma (MCL), which was recognised in the 
beginning of 1990’s as a distinct subtype of B-cell lymphoma characterised by a 
specific translocation t(11;14)(q13;q32) [4, 5]. MCL has been estimated to represent 7 - 
9% of all NHLs in Europe and a somewhat lower proportion, about 2 - 6%, in the USA 
[6]. 
 
MCL is typically a disease of middle or old age. It is usually diagnosed at an advanced 
stage. The outcome is poorer than in any of the other small cell lymphoma [7, 8]. 
Although clearly a distinct clinicopathological entity, the histopathological features of 
MCL vary. The growth pattern of the lymphoma is typically diffuse but may be also 
nodular, or the lymphoid cells may proliferate as wide collars surrounding the reactive 
germinal centres; this type of growth is called the mantle zone pattern. In addition to the 
common (or typical) MCL, a cytomorphologically more aggressive blastoid variant is 
recognised [2, 3], which is associated with a highly aggressive clinical course [7, 9-13]. 
Nevertheless, the association between different growth patterns and patient outcome is 
still poorly understood. It also appears that histological progression from the common to 
the blastoid variant is not uncommon [9, 10, 14]. 
 
The MCL-related t(11;14) leads to the overexpression of the cell-cycle regulatory protein 
cyclin D1, but this alone does not seem to explain the poor prognosis of patients with 
MCL. Abnormalities of p53 and inactivation of some cyclin-dependent kinase inhibitors 
have found to be associated with the aggressive variants of MCL and a poor prognosis 
[15-18], but the cytogenetic and molecular changes in MCL are still poorly understood. 
An imbalance between cell proliferation rate and cellular apoptosis may be involved, and 
disturbances of several apoptotic pathways have indeed been suggested to contribute to 
the pathogenesis of MCL [19].  
 
As in other NHLs, there are some clinical factors that have been reported to have 
predictive value in MCL, such as age over 60, advanced disease stage, poor performance 
status (PS), and elevated serum lactate dehydrogenase level (LDH) at the time of the 
diagnosis [9, 11, 14, 20, 21]. However, identification of universally valid prognostic 
factors has been difficult, because most of the series thus far have included a relatively 
small number of patients. In particular, the effect of histopathological features on patient 
outcome in conjunction with clinical factors has not been established. 
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There are no generally accepted optimal treatment strategies for MCL. It is still unclear 
whether anthracycline-containing regimens improve the survival of patients with MCL. 
However, none of the conventional treatments has been found to be curative, and more 
effective treatments are needed [6, 22, 23]. In younger patients high-dose therapy 
followed by autologous or allogeneic stem cell transplantation (SCT) has been considered 
to be a means to improve the poor prognosis, but the role of intensive therapy in the 
treatment of MCL is still unsettled. There is only limited information available on the 
ideal timing of SCT and on the factors that predict outcome after transplantation.      
 
The aim of this thesis is to improve our understanding of the clinical, histopathological, 
and genetic features of MCL, and to investigate their prognostic significance for patients 
with MCL.  
Review of the literature 
 
 
 
 
15
 
REVIEW OF THE LITERATURE 
 
 
 
EVOLVING CLASSIFICATION OF NON-HODGKIN’S LYMPHOMAS  
 
The non-Hodgkin’s lymphomas (NHLs) are a diverse group of diseases caused by 
malignant proliferation of lymphatic cells. In about 85% of the cases the disease affects 
the B-lymphocyte lineage and in about 15% the T-lymphocyte lineage. Lymphomas 
may originate from primitive stem cells (precursor B- or T-cell neoplasms) or from cells 
at later stages of maturation after stem cell differentiation (mature B- or T-cell 
neoplasms). An increasing understanding of the biological features of normal 
lymphocytes progressing through differentiation pathways and their genetic abnormalities 
related to the malignant transformation have permitted a more precise definition of the 
subtypes of NHLs [2, 3].  
 
The widely used classification of lymphomas by Rappaport based on the morphological 
features of the lymphomas was published in 1960s [24]. Since then several 
classifications have followed. The complexity of the lymphoid system has lead to 
various systems to categorise lymphomas, and several different classifications have 
been used simultaneously by the medical profession. Among the most widely used 
classifications have been the Kiel classification from 1974 (revised in 1988) [25] and 
the Working Formulation for Clinical Usage (WF) from 1982 [26]. In WF, the 
lymphomas were categorised according to the estimated clinical aggressiveness of the 
disease into three grades: low-grade, intermediate-grade, and high-grade malignant 
lymphomas. In the Kiel classification, on the other hand, the lymphomas were grouped 
according to their histopathological features into either a low grade or high grade of 
malignancy. The WF classification became the most widely used classification in the 
North America, whereas the Kiel classification dominated clinical practice in Europe 
[1]. 
 
The uncertainties of classification have resulted in heterogeneous categorisation of 
many lymphoma entities, variable nomenclature and variable diagnostic criteria. The 
advances in immunology and molecular genetics of lymphoid neoplasms over the last 
decades have allowed characterisation of new and previously unrecognised types of 
NHL. The Revised European-American Lymphoma (REAL) classification proposed by 
the International Lymphoma Study Group was published in 1994 to provide a unified 
international basis for both clinicians and investigators to categorise lymphomas [2]. In 
this classification lymphomas are defined for the first time by a combination of 
morphologic, immunophenotypic, genetic, and clinical attributes. One important result 
from this new approach was the recognition that lymphoma entities may have a range of 
morphological grades and express varying clinical aggressiveness. The classification 
principles of the International Lymphoma Study Group are used in the recently 
Review of the literature 
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published World Health Organization (WHO) classification (Table 1), which represents 
the first true global consensus on the classification of tumours of haematopoietic and 
lymphoid tissues [3].  
 
 
Table 1. The WHO classification of lymphoid neoplasms [3]. 
 
 
B-CELL NEOPLASMS 
 
 
T- AND NK-CELL NEOPLASMS 
  
Precursor B-cell neoplasm Precursor T-cell neoplasms 
• Precursor B-lymphoblastic leukaemia / 
lymphoma 
• Precursor T-lymphoblastic leukaemia / 
lymphoma 
 • Blastoid NK-cell lymphoma 
 
 
Mature B-cell neoplasms Mature T-cell neoplasms 
• Chronic lymphocytic leukaemia / small  • T-cell prolymphocytic leukaemia 
        lymphocytic lymphoma • T-cell large granular lymphocytic leukaemia 
• B-cell prolymphocytic leukaemia • Aggressive NK-cell leukaemia 
• Lymphoplasmacytic lymphoma • Adult T-cell lymphoma/leukaemia (HTLV1+) 
• Splenic marginal zone lymphoma • Extranodal NK- / T-cell lymphoma, nasal type 
• Hairy cell leukaemia • Hepatosplenic T-cell lymphoma 
• Plasma cell myeloma / Plasmacytoma • Subcutaneous panniculitis-like T-cell 
• Extranodal marginal zone B-cell lymphoma          lymphoma 
        (MALT lymphoma) • Mycosis fungoides / Sézary syndrome 
• Nodal marginal zone B-cell lymphoma • Primary cutaneous anaplastic large cell  
• Follicular lymphoma         lymphoma 
• Mantle cell lymphoma • Peripheral T-cell lymphoma, not otherwise 
• Diffuse large B-cell lymphomas         specified 
• Mediastinal (thymic) large B-cell lymphoma • Primary systemic anaplastic large cell 
• Intravascular large B-cell lymphoma         lymphoma 
• Primary effusion lymphoma  
• Burkitt lymphoma/leukaemia T-cell proliferation of uncertain malignant 
 potential 
B-cell proliferations of uncertain malignant  • Lymphomatoid papulosis 
potential  
• Lymphomatoid granulomatosis  
• Post-transplant lymphoproliferative disorder,     
       polymorphic 
  
  
 
 
HODGKIN LYMPHOMA 
 
• Nodular lymphocyte predominant Hodgkin lymphoma 
• Classical Hodgkin lymphoma 
Nodular sclerosis Hodgkin lymphoma  
Lymphocyte-rich classical Hodgkin lymphoma 
Mixed cellularity Hodgkin lymphoma 
Lymphocyte depleted Hodgkin lymphoma 
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MANTLE CELL LYMPHOMA  
 
 
Background 
 
In the beginning of the 1990s the NHL subtypes termed as intermediate lymphocytic 
lymphoma, mantle zone lymphoma, or centrocytic lymphoma (based on morphological, 
immunohistological, and cytogenetic features) were considered to comprise a single 
distinct subtype of B-cell NHL [4, 5]. To unify these terms under one entity the name 
mantle cell lymphoma (MCL) was proposed, and MCL was incorporated for first time as 
a unique clinicopathological entity in the REAL classification in 1994 [2]. 
Immunological studies had suggested that neoplastic cells in MCL do not originate from 
the centrocytes, as thought previously, but rather that the normal cell counterpart of MCL 
is a naive pre-germinal centre cell in the primary lymphoid follicles or the mantle zones of 
secondary follicles [4, 5, 27]. Thus, the name mantle cell lymphoma was taken into use. 
However, recent studies have detected somatic mutations of the immunoglobulin variable 
region genes in some tumours of patients with MCL suggesting a follicular / post-
follicular origin in these MCLs [28-31].   
 
According to the Kiel classification [25], MCL (identified as diffuse centrocytic 
lymphoma) belongs to the group of low-grade lymphomas but, in spite of its 
nonaggressive histological features, it carries a poorer prognosis than the other small 
cell lymphomas. In the WF classification [26] MCL is not recognised as a distinct 
disease entity, but it has been included in the subgroup of diffuse small cleaved cell or 
diffuse mixed small and large cell lymphomas of intermediate grade of malignancy, or 
in the group of follicular low-grade lymphomas.  In the REAL / WHO classification, 
MCL is recognised as having a range of morphological grades; although MCL is not 
formally graded for clinical purposes, one morphologically more aggressive variant, the 
blastoid variant of MCL is considered to be of clinical significance [3].   
 
 
Pathogenesis and biology 
 
Translocation (11;14)(q13;q32) and BCL1/CCND1 gene 
 
The characteristic cytogenetic alteration in MCL is the t(11;14)(q13;q32) [32, 33]. 
Classical cytogenetic studies detect t(11;14) in up to 65% of MCLs [34, 35], but recent 
studies using a variety of FISH techniques have shown that this translocation is present 
in nearly all MCLs [36-38]. Although t(11;14) is extremely rare in other lymphomas, it 
is not totally specific for MCL, since it has been detected in occasional atypical cases of 
chronic lymphocytic leukaemia (CLL) associated with an aggressive clinical course, as 
well as in up to 20-30% of the prolymphocytic leukaemias and in 5% of multiple 
myelomas [35, 39].  
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In the t(11;14) the immunoglobulin heavy-chain joining region in chromosome 14 is 
juxtaposed adjacent to a region on 11q13 designated BCL1 (B-cell lymphoma / 
leukaemia 1) [40-43]. The breakpoints in the BCL1 locus occur in 30 - 55% of the cases 
in the major translocation cluster (MTC) region, but additional breakpoints distal to this 
region are detected in 10 - 20% of the cases [44-46]. A new gene named PRAD1 located 
approximately 120kb downstream of the MTC breakpoint was first identified in studies 
on parathyroid adenomas with inversion in chromosome 11, and this gene was 
considered to be a putative oncogene deregulated by the t(11;14) [47-49]. In further 
studies, the PRAD1 sequence was recognised as having a high degree of homology with 
cyclins, and the new member in that gene family was renamed CCND1 encoding for the 
cyclin D1 protein [48, 50]. In t(11;14) the coding region of CCND1 is structurally 
intact, but the chromosomal rearrangement positioning the CCND1 gene adjacent to the 
enhancer region of the immunoglobulin heavy-chain gene results in upregulation of 
CCND1 and in increased expression of the cyclin D1 protein [33, 51].  
 
Cyclin D1 protein and aberrant cell cycle function 
 
In normal lymphoid cells the RNA and protein levels of cyclin D1 are extremely low or 
absent [52-54]. Although the oncogenic mechanism of cyclin D1 is not completely 
understood, the constant expression of cyclin D1 has an important role in the 
pathogenesis of MCL since cyclin D1 promotes the progression of cells through the 
main commitment checkpoint in G1- to S- phase of the cell cycle [32, 43, 55]. 
 
Regulation of the cell cycle. Cell replication is controlled by complex feedback 
pathways that regulate the passage of cells through the four phases of the cell cycle 
called the G1-, S-, G2-, and the M-phase (G stands for gap, S for synthesis and M for 
mitosis). Various combinations of complexes of cyclins and cyclin dependent kinases 
(CDKs) are essential for the progression of the cell cycle through a number of various 
cell cycle checkpoints. The cyclin/CDK -complexes are negatively regulated by cyclin 
dependent kinase inhibitors, such as p15, p16, p18, and p21. There are at least eight 
families of mammalian cyclins (cyclins A-H) acting during the various stages of the cell 
cycle. Of these, cyclins D1-D3 belong together with cyclins C and E to the so called 
G1-cyclin family that function mainly in late G1-phase [1].  
 
Cyclin D1 and the cycling cells. Cyclin D1 binds to CDK4 or CDK6 forming a 
cyclin/CDK complex, which binds to the retinoblastoma protein (pRb). This leads to 
phosphorylation of pRb and inactivation of its suppressor effect on cell-cycle 
progression. Transcription factor E2F is normally bound to the unphosphorylated pRb, 
but as a result of hyperphosphorylation of pRb, E2F is released and drives the cell to the 
S-phase (Figure 1) [33, 55]. Concordantly, although pRb seems to be normally 
expressed [56], E2F overexpression has been detected in a large proportion of MCLs 
[18].  
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Figure 1. Schematic representation of the phases of the cell cycle and the functional 
relationship of cyclin D1 in regulation of the cell cycle.  
        
 
 
Other cytogenetic and molecular changes  
 
Although the t(11;14) leads to overexpression of cyclin D1 protein and although this is 
clearly important in the oncogenesis of MCL, this alone does not lead to development of 
B-cell lymphoma in transgenic mice; cooperation with another oncogene, CMYC, is 
required [57, 58]. However, although CMYC mRNA overexpression has been found in a 
subset of MCLs, no structural gene alterations of the CMYC seem to be involved in the 
pathogenesis of MCL [59]. Cells overexpressing cyclin D1 have abnormal proliferative 
characteristics and a shortened G1-phase, but usually the cell proliferation rate in MCLs 
is relatively low [5, 22]. Moreover, there is no correlation between cyclin D1 expression 
level and cell proliferation rate [32, 56, 60], suggesting that other cellular factors in 
addition to aberrant expression of cyclin D1 are involved. Recently, an increased effect 
on cell proliferation was described when MCL cells, expressing CD40 like most B cells, 
were cultured with soluble recombinant CD40 ligand [61], and this growth-effect was 
found to be enchanced when the cells were further exposed to the cytokines interleukin-
4 or interleukin-10 [62, 63].   
 
p53 and CDK inhibitors. The p53 gene acts as a tumour suppressor by modulating 
apoptosis. In case of DNA damage, p53 activates transcription of the p21Cip1 (also 
named p21Waf1 or p21Sdi1) leading to accumulation of p21 protein, which is an important 
inhibitor of the cyclin/CDK complexes. Similarly, if the cell fails to repair the DNA 
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damage during the pause in cell replication induced by p21 accumulation, p53 may 
trigger cell suicide through apoptosis [64-66].  
 
Abnormalities of p53 are found in more than 50% of all human tumours [1]. Some 
studies have shown p53 mutations and p53 protein overexpression to occur also in the 
aggressive variants of MCL, where the effect of overexpressed cyclin D1 may be 
enhanced by loss of cyclin-CDK inhibition as a result of the p53 mutation [15-17, 67]. 
Similarly, p21 expression is lost in some aggressive variants of MCL, although the 
relationship of this aberration to p53 mutations is not clear [68]. The p27 protein may 
also be inactivated; this protein belongs together with p21 and p57 to the same CIP/Kip 
family of CDK inhibitors. In one recent series consisting of 112 patients with MCL, 
over 80% had a total or partial loss of p27 protein expression [18]. p27 mRNA 
expression was normal in this study, suggesting that the low levels of p27 resulted from 
increased degradation of activity via the proteasome pathway.  
 
Alternative pathogenetic mechanisms independent of p53 may also be operative in 
MCL. Aberrations of another CDK inhibitor, p16INK4a, have been detected in aggressive 
variants of MCL with the normal, wild-type p53 gene [68, 69]. Similarly, amplification 
and expression of the putative oncogene BMI-1, which acts as an upstream negative 
regulator of p16INK4a and p14/p19ARF gene expression, was recently reported to occur 
more often in MCL than in other types of NHLs [70]. However, the role of the BMI-1 
gene in lymphomagenesis has not been established. BMI-1 gene alterations were 
identified only rarely in MCL, and there was no relationship between BMI-1 and 
p16INK4a mRNA levels [70]. Alterations of p19 and p18, other members of the INK4a 
CDK inhibitor family, have been detected only rarely in MCL [33, 71].  
 
Abnormalities of p53 protein and inactivation of CDK inhibitors, except for p27, have 
been observed only seldom in MCL and mostly only in the aggressive variants. The 
significance of these molecular changes for the pathogenesis of MCL is not yet fully 
understood, but they are believed to be more important for the progression of lymphoma 
than for primary lymphomagenesis of MCL.  
 
DNA copy number changes. Several studies using comparative genomic hybridisation 
(CGH) and/or fluorescence in situ hybridisation (FISH) to characterise alterations in the 
frequency of DNA copy number sequences in MCL have been published [study III, 72-
75]. Although the results have differed somewhat, these studies have confirmed a 
characteristic profile of chromosomal changes in MCL different from that in other 
lymphomas. For example, in addition to trisomy 12, deletions in 13q, 11q, 6q, and 17 p 
are the most frequent aberrations in CLL [76], whereas studied by CGH gains at 
chromosomes X, 1q, 7, and 3, together with losses in 6q, X, and 1p have been reported 
in diffuse large B-cell lymphoma [77]. In contrast, in MCL the most frequent 
chromosomal imbalances are gains at chromosomes 3q (49-70%), 8q (22-30%), and 12q 
(20-30%), and the most frequent losses of chromosomes 1p (24-33%), 6q (27-37%), 9p 
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(16-41%), 11q (22-31%), and 13q (41-69%) [study III, 72-75]. DNA amplifications and 
the total number of copy number changes have been reported to be higher in the blastoid 
variant than in the common variant of MCL [72]. In line with findings on the gene level, 
loss of 17p has been found to correlate with the rate of p53 inactivation, gain of 12q 
with the frequency of CDK4 amplification, and high-level amplification of 10p12-13 
with BMI-1 amplification [72]. Interestingly, further studies on the deletion 11q (by 
FISH using a contig of YAC probes) showed deletion of 11q22-23 in as many as 49% 
of MCL samples [78]. This region is known to harbour a number of tumour-associated 
genes, including the ataxia telangiectasia mutated (ATM) gene (discussed below). These 
commonly affected chromosomal regions may also harbour unknown oncogenes or 
tumour suppressor genes. 
 
Deletion of 11q22-23 and the ATM gene. The ATM (ataxia telangiectasia mutated) 
gene is located at 11q22-23, and encodes for a large kinase that is important for DNA 
damage recognition and is required for checkpoint control of the cell cycle to reduce the 
progression of cells harbouring damaged DNA [79]. Mutations and deletions of the 
ATM gene have been found in a variety of sporadic neoplasms, including 46 - 67% of T-
PLL and 19 - 34% of CLL [80-85]. More recently, ATM mutations have been identified 
in all 7 MCLs with a 11q22-23 deletion and in 2 of the 5 MCLs with no 11q deletion 
[86], and in another study in 6 of 9 MCLs with a loss of 11q, and in 2 of 11 lymphomas 
with a normal chromosome 11 profile [87]. Consequently, it has been suggested that 
loss of this tumour suppressor gene may play an important role in the pathogenesis of 
MCL and some other lymphoid malignancies. 
     
Bcl-2 protein. BCL2 is a proto-oncogene, the activation of which prevents apoptosis 
and may lead to abnormal cell survival with accumulation of additional genetic lesions; 
this may ultimately lead to lymphomagenesis. The t(14;18) is a genetic hallmark of 
follicular lymphoma. This translocation leads to deregulated expression of BCL2, and to 
high levels of the Bcl-2 protein [88]. However, overexpression of Bcl-2 protein can be 
seen also in the absence of the t(14;18) in many other (low-grade) B-cell lymphomas 
including MCL [89].  
 
Other apoptotic pathways. Recently, a report was published on the use of an 
oligonucleotide microarray to compare the expression of some apoptosis-related genes 
in five MCLs with the expression in four non-malignant hyperplastic lymph nodes [19]. 
In addition to the Bcl-2 pathway other apoptotic pathways were found to be altered in 
MCL. The apoptosis-related genes FADD and PDCD1 were down-regulated and this 
was suggested to lead to the lack of appropriate regulation of apoptosis and to the 
accumulation of abnormal cells. The RAIDD gene, an inductor of apoptosis in 
mammalian cells, was also found to be down-regulated in MCL. Overall, these results 
suggest that, in addition to the enhanced cell cycle progression caused by overexpressed 
cyclin D1, disturbances in several apoptotic pathways may contribute to the molecular 
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genetic pathogenesis of MCL and lead to an imbalance between cell apoptosis and cell 
survival.  
 
 
Pathological characteristics  
 
Morphological features. The phenotype of MCL covers a large spectrum of 
morphological appearance: lymphomas with slowly proliferating, small-sized round 
lymphocytes at one end and large-sized pleomorphic cells and a high mitotic index at the 
other end [6, 22, 90]. Typically, as defined in the WHO classification, MCL is “a B-cell 
neoplasm composed of monomorphous small to medium-sized lymphoid cells with 
irregular nuclei, which morphologically most closely resemble centrocytes/cleaved 
follicular centre cells but which often have at least slightly less irregular nuclear contours. 
Neoplastic transformed cells, paraimmunoblasts and pseudofollicles/proliferation centres 
are absent“ [3]. In cases with a more aggressive histological picture, i.e., lymphoid cells 
with medium to large-sized nuclei and usually with a high mitotic index, the term blastoid 
or lymphoblastoid variant of MCL has been applied because the cells resemble 
lymphoblasts. There is also a separate type of blastoid variant called the pleomorphic 
variant [3, 60]. This variant is characterised by a more heterogeneous proliferation of cells 
with large cleaved to oval nuclei and a pale cytoplasm. Usually, both the lymphoblastoid 
and the pleomorphic lymphomas are included in the blastoid variant.  
 
The growth pattern of MCL is typically diffuse or vaguely nodular, but sometimes a more 
prominent nodular pattern resembling the architecture that is usually seen in follicular 
lymphoma is present. Rarely the lymphoma cells proliferate as wide collars surrounding 
the reactive germinal centres throughout the lymph node, giving the name mantle zone 
pattern [3, 4, 91-94]. Some authors believe that the mantle zone pattern represents through 
a nodular phase the initial stage of the disease, leading to the diffuse pattern of MCL [6].  
 
Immunophenotype. The neoplastic cells typically express B-cell associated antigens, 
e.g., CD19 and CD20, and surface immunoglobulins IgM and, usually, IgD. In most 
cases the cells are positive for the T-cell specific antigen CD5, but they do not express 
CD10 or CD23. Lambda-clonality is seen slightly more often than kappa-clonality. Bcl-
2 is universally positive [93-97]. Almost all cases of MCLs express cyclin D1 protein 
[32, 52-54, 98, 99].  
 
Histological progression. Histological progression to the typical large cell lymphoma 
does not occur in MCL, but progression from the common to the blastoid variant of 
MCL during the course of the disease does occur. In the few studies where serial 
biopsies have been taken during the course of the disease, blastoid transformation has 
been reported in 19 to 29% of the patients [9, 10, 14, 100]. Blastoid transformation at 
any time during the course of the disease has been shown to be associated with a poor 
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survival [9], but the clinical features, or the predictive factors related to the blastoid 
transformation per se have not been characterised. 
 
 
Diagnosis and differential diagnosis of mantle cell lymphoma 
 
MCL may be easily confused with other types of B-cell NHLs because of its 
morphological heterogeneity and resemblance to other lymphomas. For an accurate 
diagnosis of MCL the combination of morphology and immunological or molecular 
studies are needed [2, 3, 5, 101].  
 
It may sometimes be difficult to differentiate between follicular lymphoma and MCL 
with a more or less nodular pattern. MCL cells are usually not as cleaved as in follicular 
lymphoma, and large transformed cells are usually absent in MCL. In 
immunophenotyping, CD5 positivity and the absence of CD10 in MCL are useful, since 
in follicular lymphoma the reverse is often true. In atypical cases of small lymphocytic 
lymphoma (SLL)/CLL (without the characteristic pseudofollicular proliferation centres) 
morphological differentiation from MCL may be extremely difficult. Expression of 
CD5 is not helpful, since it is usually present in both MCL and SLL/CLL, but 
SLL/CLL typically expresses the CD23 antigen, whereas it is absent in most cases of 
MCL [102, 103]. Occasionally MCL may also be confused with marginal zone 
lymphoma (mucosa-associated, MALT-lymphoma), especially when situated in the 
gastrointestinal tract. Here again, the typical immunophenotype of MCL is helpful for 
differential diagnosis. As the name blastoid variant of MCL emphasises, in these 
lymphomas, the MCL cells show cytologic resemblance to lymphoblasts, and may be 
misdiagnosed as lymphoblastic lymphoma, unless proper immunophenotyping is carried 
out.       
 
Cyclin D1 plays an important role in the diagnosis of MCL. The t(11;14) is present in 
almost all cases of MCL, but currently the methods needed to demonstrate this 
translocation are not widely available for clinical practice. On the other hand, 
overexpression of cyclin D1 protein can be easily demonstrated in almost all cases of 
MCLs, and overexpression of this cyclin is rare in other lymphoproliferative diseases 
[32, 52, 54, 98, 104, 105]. Immunohistochemical detection of cyclin D1 in paraffin-
embedded tissue sections has been found to be only slightly less sensitive than mRNA 
analysis [53, 106]. Cyclin D1 expression may be demonstrated reliably also from small 
tumours and bone marrow biopsies if optimal techniques are used [107, 108]. Recently, 
a flow cytometry method to detect cyclin D1 overexpression using the monoclonal 
antibody 5D4 has been described [109]. New quantitative PCRs have been introduced 
as rapid, specific, and sensitive diagnostic methods for the detection of cyclin D1 
overexpression [110-112].   
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Clinical manifestations  
 
Typically MCL presents in middle-aged or elderly patients at an advanced disease stage 
and generalised lymphadenopathy [9-11, 14, 20, 21, 113-115]. Male predominance 
varying from 67 to 94% is reported in most studies. Extranodal manifestations of 
lymphoma are common, and more than half of the patients present with bone marrow 
involvement. The pattern of bone marrow infiltration is usually intertrabecular with 
nodular or interstitial infiltrates, but tumour cells may also be distributed 
paratrabecularly and diffusely, or as a combination of these [10, 116, 117]. Although 
bone marrow involvement is common, leukaemic disease is rather unusual at the time of 
the diagnosis [118-120]. Another typical extranodal site of the disease is the 
gastrointestinal tract, where the lymphoma typically presents as multiple polyps, a 
condition known as lymphomatoid polyposis [121-125]. Expression of the mucosal 
homing receptor integrin α4β7 may be associated with digestive tract involvement. In a 
small study of 13 patients, all seven patients with gastrointestinal involvement of MCL 
showed expression of α4β7 while none of the six patients with no gastrointestinal 
involvement expressed this integrin [126]. Other predilection sites are the spleen, 
Waldeyer’s ring, and the liver. The spleen may be remarkably enlarged, and a 
spontaneous rupture of the spleen may occur [9, 127, 128].  
 
Central nervous system (CNS) involvement has been considered to be very rare in small 
cell lymphomas [129-132]. CNS manifestation at the time of the diagnosis of MCL has 
been reported only in occasional patients in the literature [95, 133, 134], but the 
possibility that the incidence of CNS lymphoma in MCL patients might be higher than 
this has been raised by a Spanish group, who reported five (23%) out of 22 patients and 
later seven (12%) of 59 MCL patients to develop CNS involvement during the course of 
the disease [11, 135]. The CNS relapse was a relatively late event in the natural course 
of the disease: the median time of onset of CNS manifestation was 18 months after the 
diagnosis of MCL.  
 
 
Treatment results and prognosis 
 
Conventional treatment  
 
MCL brings together the worst characteristics of high-grade and low-grade lymphomas: 
the course of the disease is not indolent and the lymphoma is only rarely curable. 
Although chemosensitivity of MCL is moderate and complete remissions (CR) range 
from 20 to 50% in different series, the duration of remission is usually short. There is no 
plateau in the survival curves, the median survival time is 3 - 4 years only, and less than 
10% of all patients are alive 10 years after the diagnosis of MCL [7, 9, 11, 21, 113, 136, 
137].  
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There are no universally approved evidence based treatment strategies for MCL. It is 
still unclear whether anthracycline-containing chemotherapy regimens improve the 
outcome (Table 2). In some retrospective studies [14, 21] anthracycline-containing 
treatment has been associated with a better outcome than non-anthracycline regimens, 
but not in others [9, 11, 20]. In a prospective randomised trial on the treatment of 
advanced low-grade NHLs, the CR-rate was 26% (5/19) in MCL patients treated with 
prednimustine and mitoxantrone, as compared to 5% (1/19) in those treated with COP, 
but the overall response rates were similar [138]. There was no significant difference of 
outcome between 37 patients treated with COP and 27 patients treated with CHOP in a 
prospective randomised trial involving patients with advanced centrocytic lymphoma 
[139]. Other treatment results with the standard CHOP regimen have also been 
inconclusive. A significantly worse outcome was reported among patients with MCL 
than any other patients with low- or intermediate-grade lymphoma (reclassified as WF 
categories A through E) treated with CHOP in a study consisting of 376 patients [7].  
 
Fludarabine. Fludarabine is one of the newer purine analogs which are highly active in 
the treatment of CLL and low-grade NHLs [140-143]. However, in MCL the efficacy of 
fludarabine seems to be only moderate. The overall response rates to fludarabine 
treatment range from 33 to 63% when used as a single agent [144-146]. There was no 
difference in outcome when the combination of fludarabine and idarubicine was 
compared to single-agent fludarabine as frontline treatment of patients with MCL [147]. 
Instead, encouraging preliminary results were recently reported for a combination 
consisting of cisplatine, fludarabine, and cytarabine in a small phase II study on 
refractory NHLs which included eight MCL patients [148]. 
 
Hyper-CVAD. Considerably better results than those obtained with CHOP therapy 
have recently been reported with the Hyper-CVAD regimen (including 
hyperfractionated intense-dose cyclophosphamide, doxorubicin, vincristine, and 
dexamethasone, alternating with high doses of cytarabine and methotrexate), which was 
originally designed to treat patients with acute lymphoblastic leukaemia (Table 2). In a 
series of 45 patients an overall remission rate of no less than 94% was seen after four 
cycles, and in 25 previously untreated patients under 66 years of age following stem cell 
transplantation, the three-year overall survival (OS) was 92% and the event-free 
survival (EFS) 72% three years after treatment. The corresponding rates in a historical 
control group of previously untreated patients who had received CHOP or CHOP-like 
treatment were 56% and 28% [149]. Encouraging results with Hyper-CVAD have also 
been published in patients over 65 years of age who did not undergo stem cell 
transplantation [150], but the superiority of these regimens over CHOP needs to be 
verified in randomised studies, because case selection may introduce bias, and 
comparisons to historical controls are notoriously difficult. 
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Table 2.  Results of chemotherapy in MCL. 
 
Study  N of treated 
patients 
CR-rate  Median EFS/PFS 
(months) 
Median OS 
(months) 
Prospective randomised trials     
 
Meusers et al. (1989) [139] 
  CHOP 
  COP 
 
 
 
27 
37 
 
 
58% 
 41%,  
p = NS 
 
  
 7 
10 
p = NS 
 
 
37 
32 
p = NS 
Unterhalt et al. (1996) [138] 
   PmM 
  COP  
 
19 
19 
 
26%a 
 5%a 
 
] 8 
 
] 28 
 
Reviews of randomised trials     
 
Teodorovic et al. (EORTC) (1995) [137] 
  CHVmP-VB / ProMACE-MOPPb   
  CVP / CVP + interferon α  
 
 
29 
35 
 
 
52% 
40% 
p = NS 
 
 
19 
20 
p = NSb 
 
 
45 
45 
p = NSb 
 
Comparison with historical controls   
 
Survival fractions 
 
Khouri et al. (1998) [149] 
  Hyper-CVADc 
  CHOP (historical control) 
 
 
 
25 
25 
 
 
100% 
NR 
 
at 3-years 
72% 
28% 
p = 0.0001 
 
at 3-years 
92% 
56% 
p = 0.05 
 
Reviews of one arm therapy studies  
 
Survival fractions 
 
Fisher et al. (SWOG) (1995) [7] 
  CHOP 
 
 
36 
 
 
NR 
 
at 10-years 
           6%  (FFS) 
 
at 10-years 
8% 
Vandenberghe et al. (1997) [151] 
  Chlorambucil, COP, RT 
 
65 
 
45% 
 
24 
 
57 
 
Retrospective series     
 
Berger et al. (1994) [20] 
Anthracyclines vs. fludarabine vs. others     
 
52 
19 / 11 / 22 
 
31% 
NR 
 
14 
No difference 
 
52 
No difference 
Norton et al. (1995) [9] 
   Anthracyclines vs. others 
66 
12 / 54 
9% 
25 vs. 6% 
p = NS 
10 
No difference 
36 
No difference 
Zucca et al. (1995) [21] 
   Anthracyclines vs. others 
65 
33 / 28 
51% 
68 vs. 25% 
p = 0.001 
            44 (DFS) 
Favour for A+, 
p = 0.009 
42 
∼ 52 vs. ∼30 
p = 0.003 
Bosch et al. (1998) [11] 
   Anthracyclines vs. others 
59 
38 / 16 
19% 
15 vs. 21% 
p = NS 
NR 
- 
49 
46 vs. 69 
p = NS 
Samaha et al. (1998) [14] 
   Anthracyclines vs. others 
121 
68 / 53 
28% 
29 vs. 26% 
p < 0.001d 
11 
No difference 
37 
No difference 
Weisenburger et al. (2000) [152] 
   Anthracyclines vs. others 
68 
54 / 14 
42% 
NR 
12 
No difference 
38 
No difference 
 
CR: complete remission; EFS: event-free survival; PFS: progression-free survival; OS: overall survival; CHOP: 
cyclophosphamide, doxorubicin, vincristine, prednisone; COP: cyclophosphamide, vincristine, prednisone; PmM: 
prednimustine, mitoxantrone; EORTC: European Organization for the Research and Treatment of Cancer Lymphoma 
Cooperative Group;  CHVmP-VB: cyclophosphamide, doxorubicin, teniposide (VM26), prednisone, vincristine, 
bleomycin; ProMACE-MOPP: modified doxorubicin, cyclophophamide, etoposide (VP16), mechlorethamine, 
vincristine, procarbazine, prednisone; CVP: cyclophosphamide, vincristine, prednisone; Hyper-CVAD: 
cyclophosphamide, vincristine, doxorubicin, dexamethasone, high-dose methotrexate and cytarabine; SWOG: 
Southwest Oncology Group; RT: radiotherapy;  NS: not significant; NR: not reported; FFS: failure-free survival; DFS: 
disease-free survival; A+: anthracycline-containing chemotherapy; ∼: estimated of survival curve 
 
a
 Overall response rates (CR + PR)  80% vs. 79% 
b CHVmP-VB vs. ProMACE-MOPP: median PFS 21 vs. 16 months, (p = 0.04), median OS  65 vs. 33 months (p= 0.10) 
c Previously untreated patients who received four cycles of Hyper-CVAD before stem cell transplantation 
d The patients treated with anthracycline-containing regimen achieved significantly more frequently a CR or PR in a 
logistic regression analysis
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Radiotherapy. Radiotherapy to treat patients with local MCL may be a good choice of 
treatment, although only about one fifth of the patients present with limited disease 
[153]. A recent preliminary report suggested that the progression-free survival of MCL 
patients with stage I or II disease was longer when local radiotherapy alone or with 
chemotherapy were given than if no radiotherapy was used [154]. 
 
High-dose therapy with stem cell transplantations 
 
High-dose therapy with the support of stem cell transplantation (SCT) has been 
considered the most promising approach to improve the poor prognosis of younger 
patients with MCL. Encouraging response rates have been reported from high-dose 
chemotherapy with autologous SCT (ASCT) in MCL, the CR-rates ranging from 71 to 
100% [149, 155-160], except for one study, where only 44% of the patients achieved a 
CR [161]. However, the long-term efficacy of ASCT is still uncertain, and exclusion of 
patients with a poor performance status and of patients who are unlikely to tolerate 
aggressive therapies is likely to produce selection bias over less aggressive treatments. 
The most optimistic results have shown an estimated probability of four-year survival of 
80% [160], whereas in other studies the probability of three-year survival has varied 
from 24 to 56% [149, 161, 162]. Recently, in a preliminary report of the first 
prospective randomised trial by the European MCL Intergroup, a significant 
prolongation of event-free survival was reported in patients treated with myeloablative 
radiochemotherapy with ASCT support compared to patients treated with interferon α 
maintenance as a part of first-line treatment in chemosensitive patients with MCL [163]. 
However, there was, as yet, no difference in OS.  
 
Contamination of the autograft by tumour cells has been considered a considerable 
problem in ASCT in lymphomas with bone marrow involvement [164]. Whether ex 
vivo manipulation such as CD34+ selection of the autograft could improve the outcome 
of patients with MCL after ASCT is unclear. Effective purging of the graft seems, 
nevertheless, to be difficult in MCL: recently in a study of 19 patients with PCR-
detectable residual disease in bone marrow before high-dose therapy, eradication of the 
MCL was achieved in only two cases after immunological purging of the graft, and 
reinfusion of minimal residual disease was found to be associated with a poor outcome 
[165].  
 
Allogeneic SCT has been demonstrated to be effective in MCL. The advantages of this 
technique include a tumour-free graft and a proposed graft-versus-lymphoma effect 
[166-169]. In a series including 32 patients with poor risk MCL (88% of patients 
beyond first remission) treated with high-dose chemotherapy or fludarabine-based 
nonablative combination therapy followed by allogeneic SCT, the overall four-year 
disease-free survival rate was 41%; and for patients transplanted in CR the figure was 
100% [170].  
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Immunotherapy  
 
Various immunotherapies have been found to be promising in the treatment of 
lymphomas. Of these, rituximab, a chimeric monoclonal anti-CD20 antibody has been 
studied most widely [171]. Its anti-lymphoma activity was primarily demonstrated in 
the treatment of follicular lymphoma patients who had received prior chemotherapy 
[172, 173]. In MCL the response rates have ranged from 22 to 40% when rituximab has 
been used as a single agent. The proportions of responding patients are rather similar 
among newly diagnosed and previously treated patients, and comparable to those seen 
among patients with follicular lymphoma: the median duration of response has been 
around one year [174-176]. Although these results might suggest that rituximab 
monotherapy does not offer higher efficacy than cytotoxic chemotherapy, the 
combination of rituximab and chemotherapy has been associated with a high rate of 
molecular response in the bone marrow and the peripheral blood [177]. The use of 
rituximab for in vivo purging in conjunction with high-dose chemotherapy followed by 
ASCT is under investigation. 
 
 
Factors related to outcome 
 
Many molecular and clinicopathological variables have been investigated in 
retrospective studies to examine their prognostic and predictive value with regard to the 
outcome of patients with MCL. However, the number of patients included in most of 
these studies has been limited which has hampered the identification of factors with 
independent influence on outcome.  
 
Tumour-related factors 
 
The blastoid morphology has been found to be associated with a poor prognosis in most 
studies. The median overall survival of patients with the blastoid variant of MCL has 
been less than 24 months in most reported series [7, 10-13]. More conflicting results 
have been reported concerning the association between the different growth patterns of 
MCL and outcome. Although long survival times have been found to be associated with 
the mantle zone pattern in some studies [100, 114], this has not been the case in all 
studies [9, 10, 14, 152].  
 
p53 gene mutations or overexpression of the p53 protein are associated with a poor 
outcome, but these changes are also closely related to the blastoid morphology [15-18]. 
Similarly, enhanced cell proliferation has been shown to be associated with the blastoid 
morphology and with a poor prognosis [10, 18, 113, 178]. Interestingly, the mitotic 
index, but not the blastoid morphology, was found to be an independent prognostic 
factor in a multivariate analysis in one study [11]. In addition, loss of the expression of 
CDK inhibitor p27 has been reported to associate with decreased overall survival [18].  
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Patient-related factors 
 
Many clinical factors predict the outcome of patients with MCL. Of these, advanced 
age, Ann Arbor stage III or IV, a poor performance status (PS), peripheral blood 
involvement, splenomegaly, and an elevated serum lactate dehydrogenase level (LDH) 
have been found most frequently to associate with an unfavourable outcome [9-11, 14, 
21, 115]. However, the reported factors and their independency as prognostic factors 
vary from one study to another. Table 3 summarises the adverse prognostic factors for 
survival identified in studies with more than 50 MCL patients.  
 
The International Prognostic Index (IPI). The IPI was originally proposed for 
predicting the outcome of patients with the large cell diffuse and immunoblastic 
lymphomas [179], but it has later been adopted as a prognostic tool also in other types 
of NHL [180]. The IPI categorises patients into four risk-groups: low, low-intermediate, 
high-intermediate, and high-risk group according to five clinical variables, i.e. age (≤ 60 
years vs. > 60 years), Ann Arbor stage (I - II vs. III - IV), WHO performance status (0 - 
1 vs. 2 - 4), number of extranodal sites of the disease (0 - 1 vs. >1), and level of serum 
LDH (normal vs. elevated). The association of high or high-intermediate risk group with 
a poor outcome has been shown in some studies of patients with MCL [11, 14, 21, 115, 
152], but on the other hand, in other studies no significant association with outcome or 
only a small subgroup of patients with low risk was identified [10, 113]. These 
controversial results may, at least partly, be explained by the small number of patients in 
these studies.  
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Table 3. Statistical significance of 16 clinical factors in predicting adverse overall survival in patients with mantle cell 
lymphoma. Only series with more than 50 patients are included. Factors found to have independent prognostic significance by  
multivariate analysis are marked with an asterisk. 
 
Variable Norton et al. 
(1995)  
[9] 
Zucca et al. 
(1995)  
[21] 
Argatoff et al. 
(1997)  
[10]a 
Bosch et al. 
(1998)  
[11] 
Samaha et al. 
(1998) 
 [14] 
Andersen et al. 
(2002)  
[115] 
N of patients 66 65 80 59 121 105 
Median follow-up time 
(months) 
 
- 
 
49 
 
39 
 
29 
 
- 
 
30 
Median OS (months) 36 42 43 49 37 30 
Age > 60 .01b .003* NS NS .008b,* <.006c 
Poor PS (WHO ≥ 2) - NS <.01 .001* .001* <.001* 
Advanced stage  .01* NS NS NS .02 <.02 
B symptoms present - NS - .05 NS NS 
BM involvement .005 NS - NS NS NS 
Leukaemic disease .002 NS - NS .002* - 
Bulky disease - - - NS NS* - 
High IPI - .003 - .042 .02 <.001 
Splenomegaly .004* NS - .012* .04 <.001* 
Extranodal sites ≥ 2 - NS NS NS <.001 NS 
Anaemia - - - - .014* <.001* 
Leukocytosis - - - .049 - 0.02 
Elevated LDH - .001* NS .027 .009 0.002 
Elevated serum β2 
microglobulin 
 
- 
 
.008 
 
- 
 
- 
 
.04 
 
- 
Low serum sodium .001 - - - - - 
Low serum albumin < .001* - - - NS NS 
 
OS: overall survival; PS: performance status; BM: bone marrow; IPI: the International Prognostic Index; LDH: serum lactate dehydrogenase; NS: no 
significant effect on survival;  -: not reported  
 
a
 Multivariate analysis was not performed 
b
 Reported for over 70 years of age 
c
 Reported for over 65 years of age 
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AIMS OF THE STUDY 
 
 
 
The purpose of this thesis was to analyse the clinicopathological features and outcome 
of patients with MCL, and to examine the prognostic value of different 
clinicopathological factors.   
 
The specific aims were as follows: 
 
• To study the presenting clinical and histopathological features and their prognostic 
significance in patients with MCL. In particular, the role of the International 
Prognostic Index (IPI) in predicting the prognosis in MCL was evaluated (study I 
and IV). 
 
• To study the incidence, clinical characteristics, and outcome of patients with MCL 
and CNS involvement (study II). 
 
• To study the incidence of blastoid transformation during the course of the disease, 
the related clinical characteristics and outcome, and which factors predict 
transformation (study V).   
 
• To study DNA copy number changes and their clinical significance in MCL (study 
III). 
 
• To analyse the effect of high-dose chemotherapy supported by autologous stem cell 
transplantation to treat MCL (study VI). 
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PATIENTS, MATERIALS, AND METHODS 
 
 
 
Patients 
 
The patients were identified from the database of the Department of Pathology, Helsinki 
University Central Hospital (studies I-V). The histological sections of all consecutive 
patients originally diagnosed with lymphoma of the diffuse centrocytic type (according 
to the Kiel classification), or the mantle cell type (according to the REAL classification) 
from November 1980 to September 1999 were re-examined (K.F.). Only cases fulfilling 
the morphological criteria of MCL according to the REAL / WHO classification [2, 3] 
were included in the studies. At the time of re-examination additional 
immunohistochemical studies were performed, if the immunophenotyping performed at 
diagnosis was insufficient. In some of the older cases diagnosed before the antibodies to 
cyclin D1 and CD5 were available, no paraffine embedded or frozen material was 
available for additional stainings (n = 12). However, the morphological features as well as 
other immunohistochemical studies were typical of MCL in all these cases.  
 
In addition, the hospital records of all consecutive patients with confirmed MCL 
(according to the REAL criteria), who were scheduled for ASCT in any of the five 
Finnish transplant centres from March 1995 to September 2000 were collected (study 
VI). 
 
The immunophenotypical findings are presented in Table 4.  
 
 
Study I and II. The clinical features, treatment, and prognosis of 94 patients diagnosed 
with MCL between November 1980 and April 1996 were retrospectively analysed. The 
median follow-up time was 78 months (range 6-198 months) for all patients and 51 
months (range 6-129 months) for the surviving patients. The follow-up times were 
computed in this and the other studies from the date of the diagnosis of MCL to the 
closing date of the study. Study II examined the incidence, clinical characteristics, and 
outcome of CNS involvement of these patients.  
 
Study III. Thirty-four tumour specimens obtained from the 27 patients included in 
study I were taken for a comparative genomic hybridisation (CGH) analysis. The 
specimens were obtained from consecutive patients with available study material, 
prioritising patients with recurrent tissue samples or blastoid variant of MCL. In 
addition to the primary tumour, there were four cases where one to two relapses could 
be examined. The clinical characteristics of this cohort of 27 patients were comparable 
to the entire series. At the time of diagnosis, the median age of the patients was 62 years 
(range 45 - 80 years), and 16 (59%) were men. Two patients had stage I disease at  
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diagnosis, three stage II, and 22 stage IV. Twelve out of the 34 samples were classified 
as blastoid MCL. Twenty-one specimens were obtained from untreated lymphoma at 
diagnosis, three from persisting lymphoma after primary treatment and ten from 
relapsed lymphoma. Specimens were obtained from a lymph node (n = 23), blood (n = 
3, never the only specimen), bone marrow (n = 2), spleen (n = 2), subcutaneous tissue (n 
= 2), tonsil (n = 1), or the mesentery (n = 1).   
 
Study IV and V. The hospital records and histopathological material of 127 patients 
diagnosed between November 1980 and September 1999 were reviewed to assess the 
prognostic significance of the histopathological features of MCL. The cell proliferation 
rate was assessed by Ki-67 immunostaining and mitosis counting. In addition, 
overexpression of the p53 protein was studied immunohistochemically. Paraffin-
embedded material for immunohistochemical staining was available in 81 cases. In 
addition, immunostaining for Ki-67 had been done at the time of the diagnosis in 15 cases 
and was available for re-evaluation. The median follow-up time was 87 months (range 7 - 
238 months) for all patients and 44 months (range 7 - 169 months) for the alive patients. 
  
Of the total of 127 patients, 52 presented with the common variant MCL and had one or 
more rebiopsies taken during the course of the disease. The incidence of blastoid 
transformation during the course of the disease and the factors predictive for lymphoma 
transformation were analysed (study V). The median follow-up time was 85 months 
(range 10 - 238 months) for all patients, and 65 months (range 24 - 153) for those alive.  
 
Study VI. The results of peripheral blood stem cell mobilisation, response to high-dose 
chemotherapy, and outcome of 48 patients scheduled for ASCT treatment between 
March 1995 and September 2000 were retrospectively analysed. The median follow-up 
time of all patients was 42 months (range 14 - 164 months). At diagnosis, the median 
age was 56 years (range 31 -  69 years), and 40% of the patients were over 60 at the 
time of stem cell mobilisation. Thirty-eight patients had MCL with the typical 
histological features of MCL, and ten patients had the blastoid variant. Thirty-one 
patients (65%) were scheduled for ASCT as part of the first-line treatment, six of the 
second-line treatment, and 11 were treated after a relapse. A median of five (range 2 - 
18) prior chemotherapy cycles had been given before mobilisation. None of the patients 
had progressive chemoresistant disease at the time of stem cell mobilisation. 
 
 
Evaluation of clinical features (studies I-VI) 
 
The clinical features recorded at the time of the diagnosis included age, gender, PS, Ann 
Arbor stage [181], presence of B symptoms, the IPI [179], diameter of the largest tumour, 
sites of lymphomatous involvement, number of extranodal disease sites, and blood cell 
counts and blood chemistry. Chest X-ray, computed tomography of the chest, abdomen, 
and pelvis, and a bone marrow aspirate and biopsy were performed as  staging            
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Table 4. Immunophenotypes of the MCLs. Immunohistochemistry (from paraffin-embedded and/or frozen tissue material), 
and/or flow cytometry were used for phenotyping. 
 
 
Antigen Study I-IIa Study III Study IV Study V Study VI 
 
CD20 or CD19 positive 
 
94/94 (100%) 
 
27/27 (100%) 
 
 127/127 (100%) 
 
52/52 (100%) 
 
48/48 (100%) 
CD3 or CD2 negative 94/94 (100%) 27/27 (100%)  127/127 (100%) 52/52 (100%) 48/48 (100%) 
CD5 positive 70/82 (  85%) 26/27 (  96%)  102/113 (  90%) 42/47 (  89%) 34/36 (  94%) 
IgM positive 64/64 (100%) 25/25 (100%)   72/73   (  99%) 35/35 (100%) 13/14 (  93%) 
IgD positive 48/57 (  84%) 21/24 (  88%)   51/64   (  80%) 29/32 (  91%) 10/15 (  67%) 
Kappa clonality 34/71 (  48%) 11/25 (  44%)   38/87   (  44%) 18/42 (  43%) 8/25 (  32%) 
Lambda clonality 37/71 (  52%) 14/25 (  56%)   49/87   (  56%) 24/42 (  57%) 17/25 (  68%) 
Cyclin D1 positive 60/60 (100%) 25/27 (  93%) 105/115 (  91%) 45/48 (  94%) 26/27 (  96%) 
   
 a The lymphomas of all four patients who developed CNS involvement (study II) were CD5 positive and cyclin D1 positive  
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examinations. Involvement of extranodal sites was considered certain when confirmed by 
a biopsy. In study II, the diagnosis of CNS involvement was based on clinical findings 
and on the presence of malignant cells with a morphology consistent with MCL in the 
cerebrospinal fluid. Computed tomography or magnetic resonance imaging of the brain 
were done to detect parenchymal or meningeal infiltrations. Epidural tumour was not 
considered to be a CNS relapse. In study VI, tumour re-staging including bone marrow 
examination (if previously positive) was evaluated shortly before the start of the 
mobilisation therapy and before the conditioning therapy.  
 
 
Evaluation of morphological variants (studies IV-V) 
 
The histological biopsies taken at the time of the diagnosis and, when available, at the 
time of disease progression were reviewed and reclassified according to the 
cytomorphological variant and the architectural pattern of the lymphoma. This was 
performed by an experienced pathologist (K.F.) who had no knowledge of survival data. 
The diagnostic biopsy was taken from a lymph node (n = 86), pharyngeal tonsil (n = 
17), gastrointestinal tract (n = 12), bone marrow (n = 6), or from another extranodal site 
(n = 6). At the time of disease recurrence or progression one or more histological 
rebiopsies were taken of 40 patients (lymph node n = 21, tonsil n = 3, gastrointestinal 
tract n = 5, spleen n = 3, bone marrow n = 28, other extranodal site n = 6) .  
 
Cytological variant. The lymphomas were divided into the two cytological variants, 
the common variant and the blastoid variant, as previously described (REAL/WHO 
classification) [2, 3]. The cases with either the lymphoblastoid or pleomorphic 
morphology were included into the blastoid variant. The common variant was 
characterised by the presence of tumour cells typical of MCL consisting of small to 
medium-sized lymphoid cells with slightly irregular or cleaved nuclei. The 
lymphoblastoid variant was characterised by tumour cells with medium sized nuclei, 
small nucleoli, fine chromatin, and a scant non-basophilic cytoplasm. In the 
pleomorphic cases variation in the size and shape of the individual lymphoma cells from 
medium to large size, with coarse chromatin in some cases, were seen. Cases with only 
rare single cells or small groups of cells that resembled the larger cells in the blastoid 
variant of MCL were included in the common variant.  
 
In addition to the histological rebiopsies available in 40 patients, the cytological variant 
at the time of disease recurrence or progression could be assessed in an additional 12 
patients from cytological specimens (bone marrow aspirate / peripheral blood smears). 
Morphological analysis of these samples was performed using May-Grünwald-Giemsa 
staining. The proportion of cells with the blastoid appearance was counted in the 
lymphoid infiltrates of the bone marrow aspirates. The specimen was defined as blastoid 
MCL if more than 30% of the lymphoid cells had a blastoid morphology. A large-sized 
cell was considered blastoid if it had a small to moderate amount of pale or slightly 
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basophilic cytoplasm and a fine or only minimally condensed nuclear chromatin. One 
thousand cells in each specimen were evaluated.  
 
Architectural pattern. Three architectural patterns were defined: mantle zone (MZ) 
type, nodular type, and diffuse type. The lymphoma was of the mantle zone pattern 
when more than one half of the section area consisted of broad mantle zones of 
lymphoma cells, giving the surrounding germinal centres a nodular appearance. In the 
nodular pattern more than half of the section area contained tumour cells organised into 
nodules, somewhat resembling the structure of follicular lymphoma. The remaining 
MCLs were classified as diffuse. The architectural pattern was not evaluated in samples 
obtained from the bone marrow or in other extranodal biopsies if the biopsy was of an 
insufficient size for reliable classification.  
 
Mitotic index. A mitotic score was counted from 10 high power fields (hpf) (ocular 10 
x, non wide field view, and objective 40 x, the surface area of a hpf was 0.2 mm2). The 
proliferative activity was not evaluated from bone marrow biopsies.    
 
 
Immunohistochemistry (studies I-VI) 
 
Antibodies. Immunohistochemical staining for cyclin D1 (antibody cyclin D1-GM, 
Novocastra Laboratories Ltd., Newcastle, UK) was performed when paraffin-embedded 
material was available, unless this had already been done at the time of diagnosis. The 
monoclonal antibody DO-7 (DAKO, Glostrup, Denmark) was used for detection of p53 
protein overexpression, and a polyclonal antibody detecting the Ki-67 antigen  (DAKO) 
for identification of the cycling cells. The antibody for Ki-67 detects a protein expressed 
during the G1, S, G2, and M-phase of the cell cycle and is a widely accepted method for 
assessing the cell proliferation rate. 
 
Immunoperoxidase staining. Formalin-fixed deparaffinised tissue sections (4 µm) 
were used for the immunostainings. A standard streptavidin-biotin peroxidase technique 
was used after 15 minutes of microwave pre-treatment in 10 mmol/litre citrate buffer 
(pH 6.0). The deparaffinised tissue sections were incubated with the primary antibodies 
(dilution 1:25 for cyclin D1, 1:50 for p53, and 1:200 for Ki-67) overnight at 4°C. The 
sections were developed in 3-amino-9-ethylcarbazole (AEC). Finally, the sections were 
counterstained in Mayer’s hematoxylin and mounted in an aqueous mounting medium. 
A positive control with known antigen expression was included in each experiment. 
 
Interpretation of immunostaining results. The specimen was classified as positive for 
p53 overexpression when 5% or more of the lymphoma cell nuclei stained positively. The 
level of Ki-67 expression was assessed using a point-counting ocular grid (R.R.). At least 
200 grid cross-sections falling over the lymphoma cells were evaluated, and the number 
of cells expressing Ki-67 and located at the grid cross-sections was counted. To simulate 
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routine clinical circumstances, the Ki-67 expression level was also evaluated by another 
investigator (K.F.) who was blinded to the counting results. The results obtained by grid 
counting and simple estimation of the percentage of Ki-67 positive cells correlated 
strongly (r = 0.775, p < 0.001).  
 
 
Genetic studies (study III) 
 
Cytogenetic analysis 
 
Conventional karyotype analysis was performed routinely in 22 cases (18 patients) at 
the time of diagnosis or recurrence, as described elsewhere [77].  
 
Fluorescence in situ hybridisation (FISH) 
 
Samples from 11 patients were analysed by FISH on archival, Entellan-covered 
metaphase preparations by using a chromosome 11-specific probe to identify 
overrepresentation of the chromosome or the presence of translocation. After pretreatment 
including soaking in xylene the slides were immersed through ethanol series, fixed in a 
cold (4 C°) buffered formaldehyde-acetone mixture, washed, and air dried. Then the 
slides were incubated two times in standard saline citrate and once in Tween 20, each for 
10 min. After ethanol dehydration, in situ hybridisation was performed according to 
Cremer et al. [182]. The method has been described in a detail elsewhere [183]. 
 
Southern blot hybridisation 
 
BCL1 rearrangement was analysed in 23 cases using standard Southern blot 
hybridisation, as described elsewhere [77]. In short, DNA (7.5 µg) was digested with 
BamHI restriction endonuclease (New England Biolabs Ltd., Hitchin, UK), and the 
fragments were size fractionated in a 0.8% agarose gel. After transfer of the fragments 
onto a nitrocellulose filter (Amersham, Aylesbury, UK), the DNA was hybridised with 
the BCL1 probe for the MTC region. The probe was labelled radioactively with α[32P] 
deoxycytidine triphosphate by using nick-translation. A sample with a known BCL1 
rearrangement was used as a positive control in all experiments.  
 
Comparative genomic hybridisation (CGH) 
 
Comparative genomic hybridisation (CGH) was used to evaluate DNA copy number 
changes in MCL. CGH was performed as described by Kallioniemi et al. [184, 185], 
with slight modifications. One microgram of DNA extracted from the lymphoma (fresh 
frozen tissue, blood, or bone marrow in 31 cases, and paraffine-embedded material in 
three cases) and reference DNA extracted from the blood of a healthy donor (same sex 
as the patient) were used for the hybridisation. The tumour DNA was labelled with 
fluorescein-12-dUTP, and the reference DNA was conjugated to Texas red R-5-dUTP 
(DuPont NEN Products, Boston, MA, USA). Ten micrograms of human Cot-1-DNA 
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were used to block the binding of the repetitive DNA sequences. The results were 
analysed by using an Olympus fluorescence microscope (Tokyo, Japan) and an 
automated CGH software package (MetaSystems GmbH, Altlussheim, Germany). The 
cut-off value was 0.85 for DNA copy number losses and 1.17 for gains. If the profiles 
exceeded the cut-off value 1.5, the region was considered highly amplified. Ninety-nine 
percent confidence limits with 1% error probability were used to confirm the 
interpretation. The cut-off values were taken from negative control experiments by 
using differentially labelled male DNA vs. female DNA. In the negative controls, the 
profiles never exceeded these limits. Positive controls with known aberrations were also 
set up for each hybridisation. Chromosomes 19 and Y were excluded from the analysis 
because of the false positive results in negative controls.   
 
Loss of heterozygosity (LOH) analysis 
 
LOH analysis was performed in seven lymphomas to study 11q21-24 deletion using 
polymorphic microsatellite markers in patients from whom it was possible to obtain 
reference DNA from either the blood or the bone marrow or from other unaffected 
tissue. Thirteen polymorphic markers were selected, and they covered the region from 
11q21 to 11q24, according to the Entrez database (National Center for Biotechnology 
Information, NIH, Bethesda, MD, USA). The markers spanned a region of 33 cM with 
an average interval of 2.8 cM [186]. The used markers were D11S900, D11S1339, 
D11S1325, D11S1343, D11S938, D11S939, D11S1341, D11S1356, D11S1336, 
D11S1353, D11S933 (Genosys, Cambridge, UK), D11S1347, and D11S934 (Généthon, 
Paris, France). LOH analysis was performed as described previously [187]. Fifty 
nanograms of DNA were used for each PCR reaction (amplified in 27 cycles in a 
volume of 10 µl). The PCR products were electrophoresed in a 6% polyacrylamide gel, 
dried, and exposed to Kodak XAR film. Patient samples were designated uninformative 
when homozygous and informative when heterozygous. 
 
 
Treatment of lymphoma (studies I-V) 
 
The first-line treatments are presented in Table 5. Of the total of 127 patients, six 
patients did not receive active treatment for their lymphoma. Most of the patients 
achieved moderately intensive, usually anthracycline-containing chemotherapy (n = 84). 
Seven additional patients underwent autologous (n = 4) or allogeneic (n = 3) SCT as the 
first-line treatment after having received 3 to 7 cycles of CHOP. Less aggressive 
chemotherapy with chlorambucil (with or without prednisone) or CVP was given to 24 
patients. Six of the 22 patients with stage I or II disease were operated on or treated with 
local radiotherapy only. Patients without a satisfactory response to the first-line therapy 
were given various additional chemotherapy regimes and/or radiotherapy.  
 
 
Patients, materials, and methods 
 
 
 
 
39
Table 5. First-line therapies. 
 
Treatment Study I-IIa 
(n = 94) 
Study III 
(n = 27) 
Study IV 
(n = 127) 
Study V 
(n = 52) 
 
No treatment 
   
  5 
  
  2 
  
   6 
   
  0 
Surgery   5   0    4   0 
Radiotherapy   3   1    2   1 
Chlorambucil ± prednisone 13   5  16   7 
CVP   6   1    8   3 
CHOP / CNOP 32  4   51b 18 
M-BACOD 27 12  27 16 
ESHAP   3   1   9  5 
Othersc   0   1   4  2 
 
CVP: cyclophosphamide, vincristine, prednisone; M-BACOD: high-dose methotrexate, bleomycin, 
doxorubicin, cyclophosphamide, vincristine, dexamethasone; CHOP: cyclophosphamide, doxorubicin, 
vincristine, and prednisone with or without bleomycin; CNOP: as CHOP but mitoxantrone in place of 
doxorubicin; ESHAP: etoposide, methylprednisolone, cytarabine, cisplatin 
 
a
 Of the four patients who developed CNS involvement (study II), three received M-BACOD and one 
chlorambucil as the first-line treatment 
b
 Includes 7 patients who underwent autologous (n = 4) or allogeneic (n = 3) stem cell transplantation as 
part of the first-line treatment after 3 to 7 cycles of CHOP 
c
 Anthracycline-containing regimens 
 
 
High-dose chemotherapy with autologous stem cell transplantation (ASCT) 
(study VI) 
 
Treatment before stem cell mobilisation. Patients with mobilisation during the first-
line treatment (n = 31) had received a median of 3 (range 2 - 10) prior cycles of CHOP 
or a CHOP-like regimen (n= 3) with methotrexate or etoposide. Two or more regimens 
(a median of 7 prior cycles) had been given to the patients who underwent stem cell 
mobilisation during the second-line treatment (n = 6), and to the patients who 
underwent mobilisation (a median of 12 cycles) after relapse (n = 11).  
 
Mobilisation and conditioning regimens. The chemotherapy regimens used for 
peripheral blood stem cell (PBSC) mobilisation were: cyclophosphamide 4000 mg/m2 
(n = 29), intermediate-dose-CHOP (cyclophosphamide 1200 mg/m2, doxorubicin 75 
mg/m2, vincristine 2 mg, prednisone 100 mg/m2, n = 14), or others (n = 5). All patients 
received granulocyte colony-stimulating factor (G-CSF) 5 or 10 µg/kg s.c. 
 
The conditioning regimens were: BEAM (BCNU, etoposide, cytarabine and melphalan, 
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n = 17), BEAC (BCNU, etoposide, cytarabine, and cyclophosphamide, n = 14), and 
total-body irradiation (TBI) 12 Grays (Gy) with cyclophosphamide (n = 4). G-CSF was 
given to 33 patients after intensive therapy. After transplantation, eight patients received 
local radiotherapy (n = 7) or rituximab (n = 1) for consolidation. 
 
 
Assessment of response and survival (studies I-VI) 
 
Assessment of treatment response was evaluated as described by Miller et al. [188]. In 
short, complete response (CR) was defined as the total disappearance of all clinical 
evidence of the disease, including normalisation of the radiographic results and the bone 
marrow biopsy if abnormal before treatment. Partial response (PR) was defined as 
regression of at least 50% of all measurable disease. Relapse was defined as the 
reappearance of malignant lymphoma in a patient who had previously been in complete 
remission. Progression was defined as relapse, increase of tumour size by 25%, or 
appearance of a new tumour. The duration of remission was defined as the time from the 
documentation of a CR to relapse. Time to treatment failure (TTF) was measured from 
the date of diagnosis to the progression of lymphoma, or to death from any cause [189]. 
Overall survival (OS) was the time interval between the date of diagnosis and death. In 
study V, the time intervals between the diagnosis and the date of rebiopsy, and survival 
after rebiopsy were calculated. In study VI, the event-free survival (EFS) was measured 
from the date of transplantation to the date of progression, or to death from any cause. 
Progression-free survival (PFS) was defined as survival from the date of transplantation 
to the date of lymphoma progression. The patients who did not exhibit progression of 
the lymphoma were censored at the time of last date follow-up when TTF, EFS or PFS 
were calculated. Similarly, the patients who were alive at the time of the last follow-up 
were censored when OS was calculated.  
 
 
Statistical methods (studies I-VI) 
 
The statistical analyses were performed on a VAX 6000 computer using the BMDP 
statistical software package (studies I-III), or using the SPSS statistical program 9.0 for 
Windows (studies IV-VI). Frequency tables in all studies were analysed using the chi-
square test or Fisher's exact test. Mann-Whitney U-test was used to compare the non-
normal distributions between two groups, and Spearman’s test to examine the 
correlation between continuous variables. All survival times were estimated using the 
method of Kaplan and Meier. The univariate survival analyses were performed using 
the Mantle-Cox and Wilcoxon tests. The relative importance of prognostic factors was 
analysed using Cox’s proportional hazards regression analysis. 
 
All p-values are two-sided.
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RESULTS 
 
 
 
CLINICAL, HISTOPATHOLOGICAL, AND GENETIC FEATURES 
 
Clinical features at diagnosis (study I, IV) 
 
The median age of all 127 MCL patients was 65 years (range 30 - 90 years) at the time 
of diagnosis. Sixty-four percent were males. Although 83% of the patients had stage III 
or IV disease, the PS was usually good (WHO 0 - 1 in 85%), and only one third of the 
patients had B symptoms. Bulky tumours were rare, but 44% of the patients presented 
with more than one extranodal site of involvement. The most typical extranodal site was 
the bone marrow, and bone marrow infiltration occurred in 63% of the patients. The 
spleen, the gastrointestinal tract, and Waldeyer’s ring were other common sites of 
lymphoma involvement. Lymphoma cells were present in the peripheral blood of only 
15% of the patients. None of the patients presented with the CNS involvement. The 
patients were almost equally distributed among the four risk groups according to the IPI. 
The clinical characteristics of the patients are summarised in Table 6. 
 
 
Histopathological features at diagnosis (study IV) 
 
Histological subtypes  
 
Three various subtypes of MCL were defined according to the cytological variant and 
the architectural pattern of the lymphoma (Table 7): the mantle zone/nodular subtype of 
the common variant, the diffuse subtype of the common variant, and the blastoid 
variant, which occurred in 19% (n = 23), 64% (n = 77), and 17% (n = 20) of the cases, 
respectively. All cases of the blastoid variant had a diffuse growth pattern. Since the 
patients with the mantle zone and those with the nodular growth pattern had a similar 
outcome, and because of the small number of patients presenting with the mantle zone 
growth pattern, these patient groups were combined in further analyses.  
 
Associations between histological subtype and clinical features. There were no 
significant differences in the frequency of the clinical features between the patients 
presenting with the mantle zone/nodular and those with the diffuse subtype of the 
common variant. However, as compared with the common variant of MCL, the patients 
with the blastoid variant were more often older than 60 years (95% vs. 70%, p = 0.019) 
and presented more often with B symptoms (55% vs. 31%, p = 0.046), had more often 
bone marrow and blood involvement (90% vs. 58%, p = 0.011; and 35% vs. 11%, p = 
0.015, respectively), and a haemoglobin level of less than 125 g/l (79% vs. 45%, p = 
0.007). 
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 Table 6. Clinical characteristics at the time of diagnosis. 
 
Variable Study I 
(n = 94) 
Study IV 
(n = 127) 
 
Male sex 59% 64% 
Age  
     Median (years) 
     Range (years) 
     > 60 years 
 
66  
44 – 87 
77% 
 
65  
30 – 90 
74% 
Stage III-IV 76% 83% 
B symptoms 35% 35% 
Performance status (WHO)  ≤ 1 86% 85% 
Largest tumour  ≥ 10 cm 20% 20% 
Site of involvement   
     Bone marrow 61% 63% 
     Blood 12% 15% 
     Splenomegaly 31% 40% 
     Gastrointestinal tract 19% 20% 
     Conjunctiva/orbita   6%   5% 
     Waldeyer's ring 17% 17% 
     >1 extranodal site 40% 44% 
International Prognostic Index   
     Low 23% 15% 
     Low-intermediate 29% 30% 
     High-intermediate 27% 34% 
     High 22% 21% 
Lactate dehydrogenase  ≥ 450 U/l 38% 46% 
Thymidine kinase  ≥ 5 U/l 67% 80% 
 
              WHO: World Health Organization classification 
 
 
Table 7. Cytological variant and architectural pattern of 127 lymphomas 
at the time of diagnosis. 
 
Growth pattern of 
lymphoma 
Common  
Variant 
Blastoid variant Total 
(N) 
  Lympho- 
blastoid 
Pleomorphic 
 
 
 
Mantle zone 
 
    2 
 
  0 
 
0 
 
    2 
Nodular   21   0 0   21 
Diffuse   77 15 5   97 
ND 
 
    7   0 0     7 
 
     
 
Total (N) 
 
107 
 
15 
 
5 
 
127 
 
            ND: not definable 
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Proliferative activity  
 
The median mitotic score (number of mitoses / 10 HPFs) was 5 (range 0 - 120), and the 
median proportion of Ki-67 expressing lymphoma cells was 20% (range 4 - 80%). As 
expected, there was a strong positive correlation between the mitotic score and the Ki-
67 expression level (r = 0.548, p < 0.001). A higher median mitotic score and Ki-67 
expression level were found in the blastoid than in the common variant of MCL, but 
there was no difference in the proliferation activity between lymphomas presenting with 
the mantle zone/nodular pattern and those presenting with the diffuse subtype of the 
common variant (Table 8).  
 
Overexpression of p53 protein 
 
The p53 protein was overexpressed in 15 (19%) of the 81 cases studied. p53 expression 
was seen more often in the blastoid variant (4/10, 40%) than in the common variant 
(11/71, 15%), but this difference was not statistically significant (p = 0.082) (Table 8).    
 
 
Table 8. Proliferative activity and overexpression of p53 protein according to 
                                 the histological subtype in 127 MCL patients. 
 
Histological subtype N of 
patients 
Mitoses/10 HPFs 
Median (range) 
(n = 121) 
Ki-67 (%) 
Median (range) 
(n = 96) 
p53 
positivity 
(n = 81) 
All      127        5 (0-120)    20% (4-80%)      19% 
Common varianta     
    MZ/nodular       23        5 (0-15)    18% (7-30%)        6% 
    Diffuse       77        5 (0-44)    17% (4-80%)      16% 
    All     107        5 (0-44)b    17% (4-80%)b      15% 
Blastoid variant       20      23 (13-120)b    40% (11-80%)b      40% 
 
HPF: high power field; MZ: mantle zone 
 
a The growth pattern of the lymphoma could not be defined in seven cases 
b
 The difference between the common and the blastoid variant statistically significant (p < 0.001,     
Mann-Whitney’s U-test) 
 
 
Chromosomal features (study III) 
 
Karyotypes  
 
Very complex karyotypes with several marker chromosomes were seen in most of the 
studied 22 specimens in 18 patients. The chromosome numbers of the abnormal clone 
ranged from 39 to 49.  
 
Translocation (11;14) 
 
Of  the  evaluated  24   lymphomas,  nine   (38%)  had   tranlocation   (11;14)  or   BCL1  
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rearrangement by Southern blot hybridisation (n = 7) and/or FISH (n = 4).  
 
DNA copy number changes  
 
DNA copy number changes were found in all 34 tumours of the 27 patients who were 
studied (mean 4 changes, range 1 - 11). The most common changes were gains at 3q 
(52%), 8q (30%), and 15q (26%), and losses at 13q (41%), 1p (33%), 6q (30%), 9p 
(30%), and 11q (30%). Gains and losses were detected at a similar frequency (Figure 2).  
 
There were more DNA copy number changes in the blastoid variant than in the common 
variant (mean 6 vs. 3), but the difference was not statistically significant. High-level 
amplifications were found in five of the 12 blastoid variant cases (located at 3p14-22, 
8q23-ter, 9, 12p13, 13q21-ter, 13q22-32, 15q22-ter, and 20q13.1), but in none of the 
common variants (n = 22). In all four patients where there were serial samples available, 
a higher number of changes were seen at the time of relapse as compared to the sample 
taken at the time of diagnosis (Table 9). Most of the changes present in the sample taken 
at diagnosis persisted in the sample taken at relapse.  
 
Loss of heterozygosity at 11q. A small commonly deleted region was located at 11q22. 
LOH analysis covering the region from 11q21 to 11q24 was performed in seven cases, 
of which three lymphomas had a deletion at 11q by CGH. LOH was detected in two of 
these cases, but could not be identified in the third case by any of the markers. LOH was 
not seen in any of the four cases in which no deletion could be shown by CGH. 
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Figure 2. Summary of gains and losses in MCL detected by CGH. Each line represents 
a change in a single tumour. The gains are on the right side of the chromosome, and 
losses are on the left. High-level amplifications are marked with thick bars.(Reprinted 
by permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9. DNA sequence copy number changes in four MCL patients at the time of 
diagnosis and at relapse. 
 
Patient 
no 
(III) 
Changes at diagnosis Changes at relapse  Time 
after dg 
(years) 
 Gains Losses Gains Losses  
7 3q24-29 - a) 3q23-29, 15q21-26 a) 1p13-31 1 
   b) 12q13-14, 15q21-26 b) Xp22.1-3, 1cen-p31, 
5q14-23, 7q22-36.9, 
12q21-22, 18p  
 
 
7 
13 3q22-29 - 3q21-29, 8q, 11q14-22, 
amp 8q23-24.3 
1p22-31, 5q, 6q23-27, 
8p21-23, 9p24-q13, 13, 
17p, 21  
 
 
1 
15 7p22-q22, 
15q22-24 
11q14-23, 
15cen-q15 
7p22-q22, 15q22-23 Xp, 1cen-p22, 11q14-
23, 15cen-q15  
 
5 
17 4q32-35 
 
1p13-22, 
9p24-32, 
11q22 
4q31.3-35, 8q23-24.3 1cen-p31, 9p24-q22, 
11q22, 13q21-34  
 
6 
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OUTCOME AND PROGNOSTIC SIGNIFICANCE OF PRESENTING 
FEATURES 
 
Outcome (study I, IV, unpublished data) 
 
Almost one half of the actively treated patients (55/121, 45%) achieved CR, but the 
duration of the remissions was usually relatively short (median 16 months, 95% CI 9 - 
23 months) and only 22% of the patients were in remission five years after treatment. 
First-line treatment produced a higher CR-rate if the treatment included an anthracyline-
containing regimen or ESHAP (29%) as compared to patients who were treated with 
chlorambucil or CVP (13%), but the difference was not statistically significant (p = 
0.127). The median TTF of all 127 patients was 18 months (95% CI 14 - 22 months) 
and the median OS 34 months (95% CI 27 - 41 months) (Figure 3). There was no 
plateau in either survival curve. The survival rate was 48% at three years and 26% at 
five years. The outcome of patients with cyclin D1 positive MCL (n = 105), cyclin D1 
negative MCL (n = 10) and those with unknown cyclin D1 expression (n = 12) was 
similar.  
 
 
Figure 3. Time to treatment failure and overall survival of 127 patients with MCL. 
 
 
Prognostic factors  
 
Clinical factors (study I, unpublished data) 
 
Several clinical factors were prognostic of survival (Table 10, Figure 4). The most 
important factors by univariate analyses were advanced disease stage, presence of B 
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symptoms, a high IPI, bone marrow infiltration of lymphoma, leukaemic disease, a low 
haemoglobin level, a high blood leucocyte count, and an elevated serum LDH level at 
diagnosis. These variables predicted a low CR-rate, short TTF, and short OS. Advanced 
age (over 60 years) had no influence on the CR-rate, but was associated with short TTF 
and OS. 
 
Histopathological factors (study IV)  
 
Overexpression of p53 protein was associated with a lower CR-rate as compared to 
lymphomas with normal p53 expression (20% vs. 52%, respectively, p = 0.027), but 
neither the histological subtype, the mitotic score nor the level of Ki-67 expression 
exerted a significant effect on the likelihood of remission. Instead, all these factors were 
significantly predictive of TTF and OS (Table 10). The patients with the blastoid variant 
had the poorest outcome: the median OS was only 11 months (95% CI 9 - 14 months). 
There was no difference in outcome between patients with the lymphoblastoid and the 
pleomorphic morphology. Patients with the diffuse subtype of the common variant had 
a median OS of 35 months (95% CI 20 - 49 months) and those with the mantle 
zone/nodular subtype of the common variant of 70 months (95% CI 25 - 114 months) 
(Figure 5A).  There was no difference in the intensity of the primary treatment between 
patients with different histological subtypes; 76% of the patients with the mantle 
zone/nodular subtype received moderately intensive chemotherapy as compared to 73% 
of those with the diffuse subtype of the common variant, and to 93% of the patients with 
the blastoid variant (p = 0.23). 
 
The effects of the mitotic score and Ki-67 expression on outcome, when the highest 
tertile was used as the cut-off level, are shown in Table 10. The associations with 
survival were weaker when the median was chosen as the cut-off value instead of the 
highest tertile. Interestingly, the level of Ki-67 expression was found to predict survival 
both in the entire series and in the subset of the patients with the common variant of 
MCL (Figure 5B): 18 patients with the common variant and high Ki-67 (≥ 26%) 
expression had shorter OS (median 20 months) than the 64 patients with the common 
variant and a low Ki-67 level (< 26%,  median 45 months, p < 0.001). 
 
Multivariate analyses and prognostic value of the International Prognostic Index 
(IPI) (study I, IV) 
 
All of the five components of the IPI except the number of disease sites (and PS on 
TTF), had prognostic impact on TTF and OS univariate analyses. However, only stage 
and LDH were significantly associated with the CR-rate, and age and stage with TTF 
and OS when the components of the IPI were analysed together in a multivariate 
analyses (study I). In study IV, a high Ki-67 expression,  stage III-IV, and age over 60 
years at diagnosis were found to be independent prognostic factors for OS when the 
histological subtype, Ki-67 expression level, and the mitotic score were analysed 
together  with  the  five  components  of  the IPI in Cox’s proportional hazard regression 
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          Table 10. Outcome according to the clinical and histopathological features.        
 
Variable N 
 
Median 
TTF 
(months) 
P Median  
OS 
(months) 
P 
Total 127 18  34  
Age 
     ≤ 60 years 
     > 60 years 
 
33 
94 
 
24 
14 
 
 
0.019 
 
55 
26 
 
 
0.004 
Performance status 
     WHO 0-1 
                >2 
 
106 
19 
 
18 
13 
 
 
0.190 
 
55 
28 
 
 
0.040 
Ann Arbor stage 
     I-II 
     III-IV 
 
22 
105 
 
45 
15 
 
 
0.001 
 
71 
27 
 
 
< 0.001 
B symptoms 
     Absent 
     Present 
 
81 
44 
 
18 
13 
 
 
0.003 
 
40 
22 
 
 
< 0.001 
BM involvement 
     Yes 
     No 
 
74 
43 
 
15 
25 
 
 
0.004 
 
26 
58 
 
 
< 0.001 
Lymphoma cells in the blood 
     Yes 
     No 
 
19 
105 
 
7 
19 
 
 
< 0.001 
 
13 
40 
 
 
< 0.001 
IPI 
     Low 
     Low-intermediate 
     High-intermediate 
     High 
 
17 
33 
38 
23 
 
51 
22 
15 
9 
 
 
 
 
< 0.001 
 
75 
41 
31 
17 
 
 
 
 
< 0.001 
Haemoglobin level 
     ≤ 129 g/l 
     > 129 g/l 
 
69 
50 
 
15 
25 
 
 
0.006 
 
25 
58 
 
 
< 0.001 
Leucocyte count 
     ≤ 10 x 109/l 
     > 10 x 109/l 
 
84 
34 
 
23 
8 
 
 
< 0.001 
 
45 
13 
 
 
< 0.001 
LDH 
     < 450 U/l 
     ≥ 450 U/l 
 
61 
52 
 
25 
15 
 
 
0.003 
 
49 
22 
 
 
< 0.001 
Anthracycline-containing therapy 
     Yes 
     No 
 
91 
24 
 
19 
11 
 
 
0.077 
 
34 
28 
 
 
0.071 
Histological subtype 
     MZ/nodular, common 
     Diffuse, common 
     Blastoid variant 
 
23 
77 
20 
 
35 
18 
8 
 
 
 
< 0.001 
 
70 
35 
11 
 
 
 
< 0.001 
Mitotic score 
     < 12 
     ≥ 12  
 
84 
40 
 
23 
13 
 
 
0.001 
 
41 
13 
 
 
0.001 
Level of Ki-67 expression 
     < 26% 
     ≥ 26% 
 
65 
31 
 
23 
9 
 
 
< 0.001 
 
45 
13 
 
 
< 0.001 
p53 
     Negative 
     Positive 
 
66 
15 
 
19 
9 
 
 
0.005 
 
41 
18 
 
 
0.018 
 
TTF: time to treatment failure; OS: overall survival; WHO: World Health Organization classification; BM:  bone 
marrow; IPI: the International Prognostic Index; LDH: serum lactate dehydrogenase; MZ: mantle zone
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Figure 4. Overall survival by (A) age, (B) stage, (C) LDH, and (D) the IPI. 
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Figure 5. Overall survival (A) according to the histological subtype in all patients, and 
(B) according to the Ki-67 expression level in patients with the common variant of 
MCL. 
 
 
 
                   A   
 
                   B 
 
0 %
25 %
50 %
75 %
100 %
0 12 24 36 48 60 72 84 96 108 120 132 144 156 168
Time (months)
Pr
ob
ab
ili
ty
Blastoid variant (n = 20)
MZ/nodular subtype, common(n = 23)
Diffuse subtype, common (n = 77)
p < .001
0 %
25 %
50 %
75 %
100 %
0 12 24 36 48 60 72 84 96 108 120 132 144 156 168
Time (months)
Pr
ob
ab
ili
ty
 
Ki-67 < 26% (n = 64) 
Ki-67 > 26% (n = 18)
p < .001
Results 
 
 
 
 
51
model (Table 11). If the median was used as the cut-off value for the mitotic score and 
Ki-67 expression instead of the upper tertile, Ki-67 lost its significance, and age (RR 
2.51, 95% CI 1.49 - 4.21), serum LDH level (RR 2.31, 95% CI 1.46 - 3.65), and the 
histological subtype (RR 2.68, 95% CI 1.39 - 5.19 for diffuse vs. the mantle 
zone/nodular subtype; and RR 5.35, 95% CI 2.44 - 11.79 for the blastoid variant vs. the 
mantle zone/nodular subtype) were retained in the model. 
 
DNA copy number changes (unpublished data)  
 
None of the single DNA copy number changes nor the number of changes present were 
associated with outcome. 
 
 
Table 11. Prognostic significance of the five IPI components and histopathological 
features on survival (Cox’s proportional hazard regression analysis). 
 
Variable Relative risk 95% CI P 
 
Age 
    > 60 vs. ≤ 60 years 
 
1.78 
 
1.04 – 3.05 
 
0.035 
Ann Arbor stage  
    III-IV vs. I-II 
3.17 1.55 – 6.46 0.002 
Performance status 
    WHO 2-4 vs. 0-1  
  NS 
LDH 
    Elevated vs. normal 
  NS 
Number of extranodal sites 
    ≥ 2 vs. 0-1    
  NS 
Histological subtype 
    Blastoid vs. diffuse vs. MZ/nodular 
  NS 
Mitoses / 10 HPFs 
     ≥ 12 (upper tertile) vs. < 12 
  NS 
Ki-67 expression 
    ≥ 26% (upper tertile) vs. < 26% 
3.25 1.90 – 5.58 < 0.001 
 
CI: confidence interval; NS: not significant; WHO: World Health Organization classification;                                           
LDH: serum lactate dehydrogenase level; MZ: mantle zone; HPF: high power field 
 
 
BLASTOID TRANSFORMATION (study V) 
 
 
In serial samples, cytological progression from the common to the blastoid morphology 
occurred in 18 (35%) out of 52 patients primarily with the common variant of MCL 
(Figure 6). The minimum estimated risk of blastoid transformation was 24% at three, and 
42% at five years. Blastoid transformation took place in 10 patients at the time of first 
lymphoma relapse, in one patient at first progression of refractory disease, and in seven 
patients during later progression of the disease. At that time, all patients had systemic 
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disease, and  lymphatic cells with the blastoid morphology were detected in the peripheral 
blood in all except two patients. 
 
Only 18% of the patients with LDH < 450 U/l at presentation developed blastoid 
transformation as compared with 58% of those with a higher LDH level (p = 0.004). 
Similarly, 28% of the patients presenting with a leucocyte count ≤ 10 x 109/l developed 
blastoid transformation as compared with 67% of the patients with leukocytosis (p = 
0.049), respectively. Blastoid transformation occurred also earlier after diagnosis in 
patients with a high LDH level and leukocytosis (see Figures 2 and 3, study V). In 
addition, a higher Ki-67 expression level (median 24% vs. 17%, p = 0.023) and a higher 
mitotic score (median 5 vs. 3, p = 0.056) were typical of the tumours of the patients who 
developed blastoid transformation. Two of the three patients who had p53 overexpression 
at the time of diagnosis, developed blastoid transformation during the course of the 
disease. 
 
The median survival time after blastoid transformation was only 3.8 months, whereas as 
computed from the (latest) rebiopsy it was as long as 26 months in patients without 
transformation (p < 0.001). The respective median OS-times from the first diagnosis of 
MCL were 31 and 60 months (p < 0.001) (Figure 7).  
 
 
Figure 6. Blastoid transformation of MCL. The common variant (left) and the blastoid 
variant (right) tumours seen in the same patient. (Hematoxylin and eosin, × 400.) 
Results 
 
 
 
 
53
Figure 7. (A) Survival from the time of the rebiopsy to death of patients with blastoid 
transformation (”transformed”) and of patients with no transformation at the time of disease 
progression (”non-transformed”). (B) Survival from the initial diagnosis of the same 
patients. In addition, survival of 20 patients who had the blastoid variant of MCL already at 
the time of the primary diagnosis of MCL is shown for comparison (”blastoid at diagnosis”). 
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CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT (study II, V, 
unpublished data) 
 
 
Seven (6%) of the 127 patients developed a CNS relapse within a median time of 10 
months (range 5 - 86 months) after diagnosis. In five patients the CNS lymphoma related 
to the blastoid MCL: four of the patients presented with the blastoid variant, and in one 
patient the CNS lymphoma was diagnosed after blastoid transformation. Regardless of 
therapy with intrathecal injections of methotrexate (12.5 mg) or cytarabine (45 mg), 
survival after the diagnosis of CNS relapse was dismal (18 to 95 days, median 1.8 
months). 
 
 
RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION (study VI) 
 
 
Stem cell mobilisation 
 
Fourteen of the scheduled 48 patients (29%) failed to mobilise an adequate number of 
PBSCs (CD34+ -cells in blood > 0.020 x 109/l) for harvesting. Factors found to be 
associated significantly with mobilisation failure were a low haemoglobin level (≤ 114 
g/l) at the time of mobilisation (46% vs. 16%, p = 0.042), female sex (75% vs. 20%, p = 
0.005) and blastoid cytology (60% vs. 21%, p = 0.045). Only 1/11 patients (9%) in CR 
as compared to 13/37 non-CR patients (35%) failed to mobilise stem cells, but the 
difference was not statistically significant (p= 0.14, Fisher’s exact test). There was no 
effect on the mobilisation failure by mobilisation regimen used or the dose of G-CSF (5 
vs. 10 µg/kg). Nor was the number of prior chemotherapy cycles before mobilisation 
related to mobilisation failure, but the more cycles were given, the fewer CD34+ -cells 
were collected (p = 0.001).  
 
Among 34 patients with successful mobilisation, a median of 3.8 x 106/kg (range 1.88 - 
23.3 x 106/kg) CD34+ -cells was harvested with a median of two leukapheresis. In 
addition, after failed mobilisation, a sufficient amount of stem cells was collected from 
the bone marrow of one patient. CD34+ -cell selection was performed in 11 (31%) 
cases.  
 
 
Response to transplantation  
 
Altogether 35 patients received ASCT, 24 patients (69%) as a part of the first-line 
treatment, three patients during the second line treatment and eight patients after 
relapse. At the time of transplantation, 13 patients (37%) were in CR and 22 (63%) in 
PR. Twenty-eight patients (80%) remained in or achieved CR after transplantation. Of 
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five patients with PR (14%) after transplantation, three achieved CR later: two patients 
with minimal bone marrow infiltration by α-interferon, and one patient with a 
mediastinal tumour by radiotherapy. Two patients (5%) died of treatment-related sepsis 
and acute respiratory distress syndrome eight and six weeks after ASCT, respectively. 
At autopsy the first of these patients had no evidence of lymphoma and the second had 
minor bone marrow infiltration. 
 
Outcome. During a median follow-up time of 38 months (range 9 - 75 months) after 
transplantation, nine (29%) of the 31 patients with CR relapsed and both patients with 
PR progressed. The median EFS was 39 months, and the probability of four-year PFS 
was 50%. The estimated four-year survival after transplantation was 69% (Figure 8A). 
For patients transplanted during the first-line treatment, during the second-line 
treatment, or after relapse, the expected four-year survival after transplantation was 
62%, 100% and 75%, respectively. Splenomegaly (p = 0.045), gastrointestinal tract 
involvement (p = 0.012) and a high CRP level  (p < 0.001) at diagnosis were associated 
with a shorter PFS, and a high CRP (p = 0.013) level, and bone marrow infiltration (p = 
0.045) at diagnosis, and age over 60 years at transplantation (p = 0.051) with a shorter 
survival after transplantation. No secondary malignancies have been emerged. 
 
Figure 8B shows the survival after attempted stem cell harvest of all 48 patients who 
were intended for ASCT.            
Results 
 
 
 
 
56
Figure 8. (A) Event-free survival (EFS) and overall survival after ASCT of 35 patients 
with MCL. (B) Survival after attempted stem cell harvest in all 48 patients who were 
intended for ASCT. Thirty-four patients received an autologous PBSC transplantation, 
and one patient with mobilisation failure received stem cells collected from the bone 
marrow. Of the other 13 patients who failed mobilisation of PBSCs, two received an 
allogeneic transplant, and the remaining 11 patients were treated with conventional 
therapy. (Reprinted by permission of Taylor & Francis Group.)  
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DISCUSSION 
 
 
 
Clinical presentation of mantle cell lymphoma 
 
The clinical characteristics and prognosis of the 127 MCL patients included in this 
study support what has previously been published in smaller patient series [9, 20, 21, 
100, 113]. Typically, the MCL occurs in elderly patients at an advanced stage. In 
addition to generalised lymphadenopathy, involvement of extranodal sites, especially 
the bone marrow, was frequently seen at the time of diagnosis. However, the 
performance status of the patients was usually good and only one third of the patients 
presented with B symptoms. In contrast to the reported great preponderance of males 
(up to 94%) in most other studies [7, 9, 11, 100, 190, 191], only 64% were males in the 
present study.  
 
Gastrointestinal involvement at presentation occurs in 15 to 30% of the patients as 
assessed endoscopically [9, 11, 12, 14, 20, 114]. In this study gastrointestinal lymphoma 
was detected in 20% of the patients at the time of diagnosis. However, gastrointestinal 
MCL seems to be highly underestimated if endoscopy is performed only as directed by 
symptoms: recently gastrointestinal tract was shown to be affected in no less than 88% 
of 32 consecutive patients, who underwent systematic endoscopic examinations 
regardless of whether gastrointestinal symptoms were present or not [192]. The authors 
suggested that upper and lower gastrointestinal tract endoscopies should be considered 
as a staging procedure at presentation also in patients who have no gastrointestinal 
symptoms.  
 
The long-term prognosis of MCL is poor and this was confirmed in the present study: 
the median overall survival was only 34 months. There was no plateau in the survival 
curve, and only one fourth of the patients were alive five years after diagnosis. Despite 
this poor overall outcome, many clinical and histopathological factors were found to 
have clinically significant prognostic value.  
 
 
Prognostic significance of tumour characteristics and clinical factors 
 
The present study showed that the three histological subtypes of MCL have prognostic 
significance (study IV). The subtypes are the mantle zone/nodular subtype of the 
common variant (19% of all cases), the diffuse subtype of the common variant (64%), 
and the blastoid variant (17%). The mantle zone/nodular subtype was associated with 
the most favourable outcome (median survival 70 months) followed by the diffuse 
subtype of the common variant (median survival 35 months), whereas outcome was the 
poorest in patients who presented with the blastoid variant (median survival 11 months).  
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As summarised in Table 12, several other studies, in addition to the present one, have 
shown a highly aggressive clinical course of the blastoid variant of MCL [7, 9-13]:  
median survival times of 1-2 years have been reported in all except one study (55 
months) [152]. In that study, the CR-rate was higher among the patients with the 
blastoid variant than among the patients with the other histological types, and this may 
partly explain why the patients had a survival that was longer than is usually the case for 
patients with the blastoid variant. In the present study there was no significant 
difference regarding the intensity of the primary treatment or the CR-rate among the 
patients with the different histological subtypes. Rather, the patients diagnosed with the 
blastoid variant presented more often with other unfavourable clinical prognostic 
factors, e.g., older age, extranodal involvement, and B symptoms than did the patients 
presenting with the other histological subtypes.  
 
More conflicting results have been reported concerning the clinical significance of the 
various growth patterns of MCL. As shown in Table 12, the architectural pattern of 
MCL has had prognostic significance in some of studies but not all. The mantle zone 
pattern has been associated with long survival times in some older studies [193, 194]. 
However, the number of patients included in these studies has been relatively small, and 
other types of B-cell lymphoma, such as MALT lymphomas, may have been included, 
since immunohistochemical confirmation of the diagnosis has not always been possible 
or available. More recently, there has been only one report of an outcome benefit of 
patients presenting with the mantle zone subtype [114]. On the other hand,  Fisher et al. 
[7] have reported poorer outcome in 10 patients who had the diffuse growth pattern of 
MCL as compared to 14 patients who had the mantle zone or nodular growth pattern, 
and a similar trend was also seen in the study of Argatoff et al. [10] (Table 12). These 
reports agree with the present study.   
 
It is difficult to compare the clinical significance of the different histological subtypes 
between studies, because there are no uniform standardised diagnostic criteria for the 
different subtypes. The criteria for classification of the growth patterns are not clearly 
reported in many studies, and the rather common vaguely nodular pattern may have 
been classified as nodular in some and as diffuse in other reports. In the present study, 
the growth pattern was classified as mantle zone or nodular only when such a definite 
pattern was seen in over 50% of the tissue examined. The MCL of only two of our 
patients had the mantle zone pattern, and the data were analysed together with those 
who had the nodular pattern, as has been done in some other studies, as well [7, 10, 
152]. Also, different methods of case selection have obviously used in the different 
studies, as the knowledge of the morphological heterogeneity of MCL has gradually 
increased over the last decade. These problems clearly reflect the high variance in the 
proportion of the different histological subtypes and their controversial clinical 
significance reported in the various studies on MCL (see Table 12). 
 
The  present  study  (study IV)  showed  also  that  a  high  mitotic  index  and  a  high  
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Ki-67 expression were strongly associated with the blastoid variant morphology and a 
poor outcome, which is in accordance with earlier studies [10, 11, 18, 93, 113, 178]. 
The present work also showed that the cell proliferation rate varies strongly from one 
lymphoma to another, and that some common variant MCLs can also have a high rate of 
cell proliferation. An interesting observation was that a high Ki-67 expression was 
associated with a short survival also in a subset of patients with the common variant.  
 
Overexpression of p53 protein correlated with the blastoid variant and a poor outcome 
(study IV). However, unlike lymphomas with a high mitotic index or high Ki-67 
expression, lymphomas with overexpression of p53 responded poorly to chemotherapy, 
which probably explain the adverse prognostic influence of p53 expression. 
Interestingly, loss of p53 function has been found to be strongly associated with 
clinically resistant and aggressive tumours in general [66].  
 
In addition to the tumour characteristics, this study identified many clinical factors as 
indicators of a poor prognosis. Most important of these factors were age over 60 years, 
advanced stage, presence of B symptoms, splenomegaly, high IPI, bone marrow 
infiltration, leukaemic disease, low haemoglobin level, leukocytosis, lymphocytosis, and a 
high level of LDH in the serum at diagnosis. Most of these factors have been prognostic 
indicators in previous studies (see also Table 3), although bone marrow involvement and 
B symptoms have not previously been agreed as having prognostic significance in MCL 
[3, 9-11, 14, 21]. Nevertheless, the independent prognostic significance of these factors 
has been poorly characterised, especially in relation to the histopathological features. 
Multivariate analyses encompassing the tumour characteristics according to the 
architectural pattern, the cytological variant, and cell proliferation activity have not been 
performed previously. 
 
Independent prognostic factors. The IPI is one of the most popular prognostic 
indicators of NHLs. It was originally proposed for predicting outcome in large cell diffuse 
and immunoblastic lymphomas, but it has been adopted as a prognostic tool also in other 
types of NHLs [179, 180]. The IPI may have prognostic value also in MCL, although 
rather conflicting results have been reported [11, 14, 21, 113, 115, 152]. The present 
findings suggest that the IPI components selected on the basis of survival analyses in 
other types of NHLs may not be optimal for MCL (studies I, IV). Firstly, although the IPI 
had a strong prognostic correlation with patients outcome, the IPI could not discriminate 
survival between the low-intermediate and high-intermediate risk groups. Secondly, 
although all IPI components, except for the number of extranodal disease sites had 
prognostic significance on outcome by univariate analyses, it was only age, stage, and 
LDH that contributed significantly to survival when all IPI components were analysed 
together in Cox’s proportional hazard regression model. Thirdly, the histological subtype 
and Ki-67 expression were found to improve the prognostic model when analysed 
together with the IPI components in Cox’s multivariate analysis, but two of the IPI 
components, the performance status and the number of extranodal disease sites had no 
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Table 12. The incidence and prognostic significance of the cytological variant and the architectural pattern of lymphoma in patients with mantle cell 
lymphoma reported in the recent literature. 
 
Variable Present 
study 
Fisher  
et al. [7] 
(1995) 
Norton  
et al. [9] 
(1995) 
Pittaluga et 
al. [100, 118] 
(1996) 
Argatoff  
et al. [10] 
(1997) 
Majlis  
et al. [114] 
(1997) 
Samaha  
et al. [14] 
(1998) 
Bosch  
et al. [11] 
(1998) 
Yatabe  
et al. [12] 
(2000) 
Weisenburger 
et al. [152] 
(2000) 
Bernard  
et al. [13] 
(2001) 
All patients            
  N of patients 127 36 66 55 80 46 121 59 128 68 187 
  Median follow-up (months) 87 NRa NR NR 39 22 NR 29 NR 18b 24b 
  Median OS (months) 34        NR 36 32 43 NR 37 49 30%c 38 NR 
 
Incidence  (%) 
   MZ 
   Nodular 
   Diffuse 
 
2% 
17% 
64% 
 
- 
39%d 
28% 
 
9%e 
30%e 
61%e 
 
13%e 
- 
87%e 
 
6%e 
16%e 
78%e 
 
26%e 
13%e 
61%e 
 
0 
34%e 
66%e 
 
0 
  5% 
85% 
 
17%e 
38%e 
45%e 
 
22% 
22% 
24% 
 
- 
- 
- 
   Blastoid variant 17% 33% 15%e 2%e 6%e 4%e 8%e 10% 16%e 26% 21% 
 
Median OS (months) 
   MZ, common 
   Nodular, common 
   Diffuse, common 
   Blastoid 
 
- 
70d 
35 
11 
 
- 
i
 
      60d, f 
36f 
16f 
 
NRg 
NRg 
NRg 
- 
 
98 
- 
41 
- 
 
- 
47d 
39 
15 
 
100%h 
50%h 
50%h 
- 
 
- 
NRg 
NRg 
NRg 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
- 
i
 
50d 
15 
55 
 
- 
- 
- 
- 
   P value < 0.001 0.05 NS NS NS NR NS - - 0.001 - 
 
Median OS (months) 
   Common variant (all) 
   Blastoid variant 
 
35 
11 
 
 
 
42 
24j 
 
 
 
 
45 
15 
 
 
 
 
NRg 
NRg 
 
50 
18 
 
48 
14 
 
 
 
 
53 
15 
   P value < 0.001  0.02  0.001  NS 0.007 < 0.001  < 0.001 
 
Blastoid transformation  
N / Evaluated (%) 
18 / 52 
(35%) 
- 11 / 50  
(22%) 
3 / 16 
(19%) 
8 / 37  
(22%) 
- 24 / 82  
(29%) 
 
- 
 
- 
 
- 
 
- 
 
OS: overall survival; MZ: mantle zone pattern; NR: not reported; NS: not significant 
a  All patients have died 
b
  Median follow-up reported for the surviving patients 
c
  Five-year survival 
d  MZ and nodular cases included 
e  The proportion of different growth patterns have been reported including the blastoid variant of MCLs  
f  Estimated on the basis of the survival curve                         
g  Reported as no difference in outcome 
h  Three-year survival 
i
 No difference in outcome between patients with the MZ and nodular growth pattern of MCL 
j  Median OS reported for cases showing the blastoid variant of MCL at any time during the course of the disease 
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independent prognostic value. It is clear that the current study is too small to establish any 
reliable prognostic model in MCL, but the findings strongly suggest that a better 
prognostic tool might be obtained by including a factor related to the cell proliferation rate 
(as Ki-67 expression) and, possibly, the histological subtype as components in the index 
(together with age, stage, and serum LDH).  A multicentre collaborative study is needed 
to verify the general validity of the present findings, and to identify the optimal set of 
factors for a prognostic index specifically designed for MCL.  
 
 
Chromosomal features 
 
The characteristic genetic abnormality in MCL, t(11;14) or the BCL1 rearrangement was 
found in 38% of the studied 24 patients (study III). We studied the translocation 
breakpoints only for the MTC region, which covers 30-50% of the known breakpoints. 
This explains the relatively low frequency of detected translocations in this study as 
compared to recent studies, which have shown that this translocation is present in nearly 
all MCLs [37, 38]. These studies have used a variety of FISH techniques with a proper set 
of probes. 
  
As t(11;14) leads to overexpression of cyclin D1, which regulates the cell cycle in the 
early S-phase, cell proliferation markers might be powerful prognostic factors in MCL. In 
line with this hypothesis, we have shown that a high cell proliferation rate is an 
independent predictor of a poor prognosis of patients with MCL (study IV). However, the 
cell proliferation rate is usually relatively low in MCL, and no correlation between the 
level of cyclin D1 overexpression and cell proliferation rate has been detected [32, 56, 
60]. Thus, although cyclin D1 certainly has a crucial role in the pathogenesis of MCL, it 
alone seems not explain the poor prognosis of these patients.  
 
Conventional karyotype analyses have shown that MCLs have very complex and, in 
many cases, chaotic chromosome abnormalities [90]. Indeed, individual changes may be 
very difficult to detect by G-banding analysis. CGH provides a method to study changes 
in the DNA copy number of the whole genome based on simultaneous hybridisation of 
differentially labelled tumour and normal DNAs on normal metaphase chromosomes. In 
our series of the 22 common variant and 12 blastoid variant of MCL studied by CGH 
(study III), complex but highly concentrated DNA copy number changes were seen. 
DNA copy number changes were found in all cases, and eight regions were involved in 
more than 25% of the cases. The most common changes were gains at 3q, 8q, and 15q, 
and losses at 13q, 1p, 6q, 9p, and 11q. Most of the individual alterations have been 
observed also in other NHLs, but the profile and frequency of the imbalances seem to be 
relatively characteristic for MCL [76, 77, 195-201]. Furthermore, the profile of the 
chromosomal abnormalities reported in later MCL series studied by CGH are well in 
accordance with the present findings [72, 73, 75].  
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In previous studies the blastoid variant of MCL has been associated with more 
cytogenetic or molecular abnormalities, such as tetraploid chromosome clones, mutations 
or deletions of p53, and inactivation of negative cell cycle regulatory proteins than the 
common variant of MCL [16, 68, 69, 178]. In agreement with this, the present study 
showed that the median number of DNA copy number changes tended to be higher in the 
blastoid type than in the typical MCL cases. All five lymphomas showing high-level 
amplifications in the present study were of the blastoid type. Later, according to the 
observations of a larger number of patients, the number of chromosome imbalances and 
DNA amplifications were reported to be significantly more frequent in the blastoid than in 
the typical tumours, and gains of 3q, 7p, and 12q, and losses of 17p were seen more often 
in the blastoid variant than in the common variant [72]. In that study also gains of 3q and 
12q, and losses of 9p were associated with a shorter survival.  
 
Two of the frequent aberrations detected by CGH analysis, gain of 3q and deletion of 11q, 
were of specific interest (study III). Trisomy 3 is one of the most common numerical 
aberrations in NHL and is typical of the diffuse large B-cell lymphoma [202, 203]. 
Trisomy 3 has been found previously only in a few MCL tumours by conventional 
cytogentic analysis [204]. In the present series, gain of 3q was the most common 
aberration and it was detected in 52% of the patients with the minimal common region 
located at 3q26.1-27. Although the Spanish group found the gain of 3q to be more 
frequent in the blastoid than in the common variant MCL [72], no less than 70% of the 
patients with the common MCL variant showed this aberration in a recently published 
series [75]. Accordingly, this area may harbour an oncogene or oncogenes that are 
important for initial lymphomagenesis or progression in MCL. Zinc finger protein 
BCL6/LAZ3, which is known to be activated by translocation in some B-cell lymphomas, 
has been mapped to 3q26-27 [205, 206], but amplifications or rearrangements of the 
BCL6 gene have been found to be virtually absent in MCLs [72, 207].  
 
Deletion of the long arm of chromosome 11 is one of the most common chromosomal 
aberrations observed in lymphoid neoplasms [208-210]. In the present study, losses of 
11q14-24 were found in 30% of the cases with the minimal common region mapped to 
11q22. LOH analysis supported this result, as all the markers exhibiting LOH were 
mapped to 11q22-23. In further studies using interphase FISH, a deletion at this region 
has been found in up to 49% (20/41) of MCLs [78]. Consistent with these results, 
deletion of the same common minimal region in 11q has been reported frequently also 
in CLL [209, 211] and diffuse large cell lymphoma [212], suggesting that this area is a 
potential candidate region for a tumour suppressor gene involved in MCL as well as in 
CLL and diffuse large cell lymphoma. The region 11q22-23 is a very gene-rich area and 
contains several known or putative malignancy associated genes. Recently, the 
PPP2R1B gene was shown not to be the likely target of 11q22-23 deletion in MCL or 
CLL [213], but one of the suggested tumour suppressor genes in this region is the ATM 
gene, which is known to code for a protein that is critically involved in the cellular 
response to DNA damage. Ataxia-telangiectasia patients with homozygous ATM 
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mutations have an increased risk of leukaemias and lymphomas [214]. Furthermore, 
frequent inactivating mutations of the ATM gene have been reported in patients with T-
PLL [80-82] and CLL [83, 84, 215]. More recently, ATM mutations have been 
identified also in MCLs associated mainly with 11q22-23 deletions, and with a same 
frequency both in the common and the blastoid variant MCL [86, 87, 216, 217]. 
Altogether these results suggest that ATM gene may be involved in early steps of 
tumour development in MCL and other malignancies. 
 
In accordance with previously reported cytogenetic findings [218], we also found more 
changes in samples taken from the relapsed lymphomas than in those taken from 
untreated lymphomas of the same patients. To our knowledge, the DNA copy number 
changes studied by CGH have not been compared between the primary and recurrence 
MCL tumours elsewhere. Although the number of patients with sequential samples was 
small in our study, interestingly, some changes including the deletion at 11q and the gain 
on 3q, were always seen both in the primary and recurring lymphomas. Taken together 
with the other results this indicates that the deletion of 11q and gain of 3q may be early 
changes in MCL.  
 
 
Clinical significance of blastoid transformation  
 
In addition to patients who present with the blastoid variant of MCL at diagnosis, there 
is a remarkably large proportion of patients who have cytological transformation of the 
common variant to the blastoid variant during the course of the disease. In accordance 
with earlier findings [9, 10, 14, 100] (see Table 12), such a change was found in 18 
(35%) of the 52 patients who had sequential biopsies taken at the time of disease 
progression (study V). The minimum estimated risk of blastoid transformation was 24% 
at 3 years and 42% at 5 years. In another study blastoid transformation has been 
reported in 14 (70%) of the 20 autopsy-verified cases [9].  
 
In line with the poor outcome of patients presenting with the blastoid variant of MCL, 
overall survival was also significantly shorter among the patients who had blastoid 
transformation during the course of the disease (median survival 31 months) compared 
with patients who did not have this transformation at rebiopsy (median survival 60 
months) (study V). Blastoid transformation at diagnosis or at any time during the course 
of the disease has been shown to be associated with a highly aggressive clinical course 
in one of the previous studies [9]. In two other studies where survival was assessed, 
blastoid transformation was not found to have a significant effect on outcome [10, 14], 
although the blastoid morphology at diagnosis did predict an unfavourable prognosis in 
one of these studies [10]. The authors suggested that a lead-time bias may explain the 
similar outcome following rebiopsy between patients with and without transformation, 
since rebiopsy was taken remarkably later after the initial diagnosis of patients with 
transformation than of patients without. In contrast, the time interval between the 
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sequential biopsies was roughly similar in patients with (median 32 months) and without 
(median 26 months) detected transformation in the present study.  
 
Interestingly, an increased risk of blastoid transformation during the course of the 
disease was seen in patients with blood leukocytosis, an elevated serum LDH level, and 
a high cell proliferative activity of lymphoma at the time of the diagnosis. Blastoid 
transformation occurred also earlier after diagnosis in patients with leukocytosis and 
elevated LDH. To our knowledge, factors predictive of blastoid transformation have not 
been analysed previously.  
 
As described in the previous chapter, more cytogenetic or molecular abnormalities have 
been detected in the blastoid than in the common variant MCL. However, the underlying 
molecular pathogenesis related to the development of blastoid transformation de novo or 
later during the course of the disease is still unknown. Several findings support a 
hypothesis that aberrations of the p53 gene might be involved in such progression of 
MCL. Firstly, mutations of p53 and overexpression of p53 protein occur more often in 
lymphomas with the blastoid than the common variant [15-17]. Also in the present study 
blastoid MCLs at presentation tended to show overexpression of p53 protein more 
frequently than the common MCLs (40% vs. 15%) (study IV). Secondly, the occurrence 
of p53 mutations has been suggested as one mechanism in the transformation of CLL or 
follicular lymphoma into the diffuse large B-cell lymphoma [219-221]. In line with this 
concept, we observed that two of the three patients who had the common variant of MCL 
with p53 overexpression at diagnosis developed blastoid transformation during the course 
of the disease (study V). Similarly, Greinen et al. [16] reported progression from the 
common to the blastoid variant in two of the four MCL patients showing the p53 
mutation. However, further molecular studies based on serial biopsies are needed to 
confirm the role of p53 and to establish other putative mechanisms that may be involved 
with blastoid transformation.  
 
Importantly, the present findings suggest that development of CNS lymphoma in MCL 
is relatively frequent and strongly related to the blastoid morphology. Although CNS 
involvement has been considered to be very rare in small cell lymphomas [129-132], the 
disease relapsed with CNS involvement in seven (6%) of the total of 127 patients during 
follow-up. Five of these patients had the blastoid variant of MCL at the time CNS 
lymphoma was diagnosed. The prognosis after CNS relapse was very poor regardless of 
intrathecal chemotherapy. The findings by Montserrat et al. [11, 135] are in accordance 
with those of ours: there were seven (12%) CNS relapses in 59 patients with MCL. 
 
 
Treatment results 
 
Conventional therapy. So far, there is no generally approved standard therapy for 
MCL. This explains why the patients in our series, as well as in other retrospective 
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series, have received rather heterogeneous treatments. In the present study, most of the 
patients (76%) received anthracycline-containing regimens (or equivalent) as first-line 
treatment, and 20% were given chlorambusil with or without prednisone, or COP/CVP. 
Six of the patients did not receive active treatment for their lymphoma, and the 
remaining patients were treated by local radiotherapy only, or local disease was 
operated. Although almost one half of the actively treated patients achieved a CR, 
relapses occurred usually soon: the median duration of remission was only about 1.5 
years. None of the conventional chemotherapeutic regimens was curative. First-line 
treatment with anthracycline-containing chemotherapy showed neither significant 
benefit on CR-rate, TTF nor survival as compared with non-anthracycline containing 
regimens.   
 
As stated in the review section (pages 24 - 26), and in line with our findings the results 
of treatment with conventional therapy have been poor in MCL, and there was no clear 
improvement in the results with regimens containing anthracyclines as compared with 
regimes without anthracyclines. However, most of the published studies on the 
management of MCL have included relatively small number of patients, and only two 
small prospective trials in MCL have been carried out [138, 139]. In one retrospective 
study including 65 MCL patients, anthracycline-containing regimens showed a survival 
benefit in patients of the low- or low-intermediate risk IPI categories [21]. None of the 
other series have been able to confirm a survival benefit of anthracylines in MCL [9, 11, 
14, 20, 138, 139]. Interestingly, the Hyper-CVAD regimen has yielded considerably 
better treatment results than traditional chemotherapy regimens; here historical controls 
were used [149, 150]. However, it can be concluded that none of the current 
conventional chemotherapies are curative in MCL, and more accurate and efficient 
therapies are needed. During recent years, promising results have been published in 
some preliminary reports of small non-randomised MCL series using high-dose therapy 
and autologous or allogeneic stem cell transplantation [149, 155-159, 162, 167], but the 
role of stem cell transplantations in treating MCL is not yet clear.   
  
Autologous stem cell transplantation. In the present study, the results of high-dose 
therapy supported with ASCT were retrospectively analysed in a series of 48 
consecutive patients treated in five Finnish transplant centres in 1995 to 2000 (study 
VI). Altogether, 35 out of 48 scheduled patients underwent ASCT, 24 as a part of first-
line treatment and 11 patients later as a part of subsequent therapy. The overall response 
rate was 94% in these patients, and the expected four-year PFS was 50% and overall 
survival 69% following ASCT, respectively. There was, regrettably, no plateau in the 
EFS curve, and late relapses occurred even three years after the ASCT. 
 
In line with our findings, high CR-rates after ASCT have been reported in most 
previous studies [149, 155-160, 162, 222]. Most of these studies have concluded that 
ASCT is an efficient treatment of patients with MCL [149, 155-159, 162], although the 
survival probabilities after ASCT varies widely between various studies. Comparison 
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between these retrospective studies is difficult because of variable patient selection. The 
number of included patients has been relatively small (only a few series include more 
than twenty patients), and the median follow-up time after transplantation has exceeded 
three years in none of the series. Most interestingly, the preliminary results of the first 
prospective randomised trial comparing ASCT and α-interferon maintenance as a part 
of first-line therapy in chemosensitive patients showed a significant prolongation in EFS 
in the group of patients treated with ASCT [163]. However, the follow-up time is still 
too short to show a significant difference of overall survival between these patient 
groups. In accordance with our findings, the prospective study also showed no plateau 
in the EFS curve after ASCT, at least not thus far. Although the prognosis in MCL may 
be improved with high-dose therapy supported by ASCT, late relapses do occur, and it 
is not yet known in what proportion of patients continuous remissions may take place. 
 
Graft contamination has been considered to be a considerable problem in ASCT to treat 
lymphomas with bone marrow involvement [164, 223]. Another likely cause of relapses 
after ASCT is the persistence of residual disease despite of the use of high-dose therapy. 
It is not known if selection of the autograft could provide a better outcome after ASCT 
in MCL. Only two out of 11 patients treated with a CD34+ -selected graft in the present 
series has progressed, but no significant difference in outcome was seen as compared 
with the patients who had a non-selected graft (study VI). However, effective 
immunological purging of the graft below the level of PCR detection has been shown to 
be more difficult in MCL than in other lymphomas [165, 224]. Interestingly, 
preliminary reports claim that there was a high number of molecular responses in blood 
and bone marrow of MCL patients who got in-vivo purging using the anti-CD20 
antibody, rituximab, in combination with the ASCT [225-228]. Whether rituximab or 
other immunotherapies in combination with high-dose therapy can improve the long-
term outcome of MCL patients remains to be seen.  
 
The ideal timing of ASCT to treat MCL and the prognostic factors affecting the 
outcome following ASCT are still poorly known. Although the results of some studies 
have supported early high-dose treatment [149, 160], our study indicated that the 
outcome of the patients transplanted after relapse was similar to that of the patients with 
ASCT performed during the first- or second-line treatment (study VI). However, the 
patients who were transplanted after relapse represent a more selected patient group 
with a response to therapy for the recurrent disease and a successful mobilisation of 
stem cells. A blastic morphology and three or more chemotherapy regimens prior to 
transplantation have been previously reported to predict a shorter EFS after ASCT 
[229]. In the present study, splenomegaly, gastrointestinal tract or bone marrow 
involvement, and a high CRP level at the time of diagnosis of MCL were associated 
with a poor outcome after ASCT. Also patients over 60 at the time of transplantation 
had a poorer outcome than younger patients.  
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A satisfactory number of progenitor cells may be sometimes difficult to mobilise [230,  
231]. Of notice, in the present study, mobilisation of PBSCs failed in 29% (14/48) of 
the patients who were originally intended for treatment with ASCT (study VI). Most of 
the patients received cyclophosphamide or CHOP as mobilisation regimens together 
with G-CSF. There was no significant difference in mobilisation failures between 
cyclophosphamide and CHOP, or the other regimens. Neither did the dose of G-CSF (5 
vs. 10 µg s.c) have any impact on mobilisation success. Instead, female sex, blastoid 
cytology, and a low haemoglobin level shortly before the start of the mobilisation 
therapy were associated with the mobilisation failure. Most patients who had achieved 
only a few chemotherapy cycles before mobilisation therapy had other prognostic 
factors for an unsuccessful mobilisation, which may explain why the number of prior 
chemotherapy cycles was not associated with the mobilisation failure in the present 
study. However, the number of prior chemotherapy cycles affected adversely the 
number of harvested CD34+ -cells, which is in accordance with previously reported 
results on PBSC harvesting in lymphomas and other malignancies [232-234]. No 
predictive factors for mobilisation failure in MCL seem to have been previously 
reported, but in line with our finding, Khouri et al. [149] have reported that nine (31%) 
out of 29 MCL patients considered for ASCT failed to have an adequate number of 
PBSCs following G-CSF mobilisation. Importantly, successful mobilisation of PBSCs 
in MCL seems to be complicated in a remarkable proportion of the patients. As 
evidence of the importance of intensive treatment supported by ASCT in the treatment 
of MCL is increasing, more efficient mobilisation therapies are needed to make ASCT 
available for all potential patients who otherwise tolerate intensive treatment. 
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SUMMARY AND CONCLUSIONS 
 
 
 
The main conclusions of the present study are: 
 
1. Confirming the findings of previously published smaller series, MCL presented 
typically in elderly patients with an advanced stage disease and often with 
extranodal involvement. Although almost half of the patients achieved complete 
remission with conventional chemotherapy, the duration of the ensuing remission 
was usually short and the general outcome was poor: the median overall survival 
was approximately 3 years.  
 
2. The blastoid variant of MCL is associated with a high cell proliferation rate and an 
aggressive clinical course according to previous studies. The present study showed 
that also other tumour characteristics at presentation have considerable prognostic 
significance. Three histological subtypes of MCL were characterised: 1) the mantle 
zone/nodular subtype of the common variant was associated with the most 
favourable outcome followed by 2) the diffuse subtype of the common variant, 
whereas 3) the blastoid subtype was associated with the most aggressive clinical 
course and a median survival of less than one year. Furthermore,  Ki-67 expression 
was an important overall prognostic factor, and also separately among the patients 
with non-blastoid MCL. 
 
3. The impact of the histopathological features of MCL on patient outcome in 
conjunction with clinical factors has not been previously established. Of the clinical 
factors, an age over 60, advanced disease stage, and an elevated serum LDH level at 
diagnosis were independent prognostic factors of a poor outcome. Importantly, the 
prognostic model improved when Ki-67 expression or the histological subtype was 
analysed together with the five components of the IPI. This study showed that IPI 
may not be an optimal prognostic tool for MCL, and a better prognostic model 
might be developed by including Ki-67 expression and, possibly, the histological 
subtype in the index.  
 
4. The risk of CNS involvement was higher in MCL than is generally considered in 
small cell lymphomas. Importantly, this study showed that CNS relapse was 
strongly associated with the blastoid morphology.   
 
5. Transformation from the common to the blastoid variant during the course of the 
MCL is know to occur, but the clinical significance of blastoid transformation has 
not been established. In this study the minimum estimated risk of blastoid 
transformation was over 40% at 5 years, and blastoid transformation contributed 
significantly to a poor prognosis in MCL. The risk of transformation was higher in 
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patients with elevated serum LDH level, leukocytosis, and a high cell proliferation 
of lymphoma at diagnosis than in patients who did not exhibit these characteristics.  
 
6. Study III was the first one in the literature to examine the DNA copy number 
changes by CGH in MCL. The study showed a characteristic profile of 
chromosomal changes: the most common gains were located at 3q, 8q, and 15q, and 
the most common losses at 1p, 6q, 9p, 11q, and 13q. In concordance with a more 
aggressive clinical course, the number of changes tended to be higher in the blastoid 
than in the common variant, and high-level amplifications occurred only in the 
blastoid cases. More changes were also seen in relapsed lymphomas than in 
untreated lymphomas of the same patients. Most importantly, the finding of a small, 
commonly deleted region in 11q22 has resulted in further investigations to identify a 
tumour suppressor gene, which could be involved in the pathogenesis of MCL and 
other malignancies. Also, the gain of 3q, which was seen in more than half of the 
patients, indicates that this area may contain an oncogene or oncogenes important 
for tumour initiation or progression in MCL. 
  
7. Patients who were treated with the high-dose therapy supported by ASCT had 
higher response rate and longer survival times than in conventionally treated MCL 
patients in general. Together with previous data, this confirms the ASCT to be en 
effective treatment in MCL, although possible survival benefit remains to be studied 
in prospective trials. However, this study showed no plateau in the event-free 
survival curve after ASCT, but relapses were seen even after three years. This study 
can not answer the question of whether continuous remissions can be reached by 
ASCT in a proportion of the patients or not. 
 
This study has shown that several tumour characteristics and clinical factors have 
considerable prognostic significance in MCL, and that there is a need for a new 
prognostic model designed for MCL to be identified in a multicentre collaborative 
study. It is likely that our improving understanding of the genetic changes related to 
MCL will aid the evaluation of the patients’ prognosis. Ongoing studies on gene 
expression profiling using novel micorarray technologies are likely to widen the 
knowledge of the pathogenesis of MCL, as well as to identify the genes related to 
specific disease characteristics, like blastoid transformation. Hopefully these studies 
will also widen our understanding of the mechanisms related to treatment resistance and 
the generally poor prognosis of patients with MCL. Ultimately this approach may 
provide a platform for the development of novel, more accurate treatment strategies.      
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